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1. Introduction 
 Pharmaceutical dosage forms have to meet several requirements in order to be 
released on the market. Most of these involve parameters that, while key in 
determining product performance, are not specific to the product itself and have little 
to no connection to the natural laws and phenomena that determine the functionality 
of the final dosage form. This probably contributes to the fact that despite the tight 
quality control maintained in the pharmaceutical industry many of the recalls happen 
because of failures to meet specifications. While specific formulation properties and 
their investigation have received a lot of attention and several advanced 
characterization techniques have been developed a better understanding of the final 
product is required to improve design and manufacturing and thus avoid unnecessary 
batch failures and recalls. 
 Dissolution is arguably the most important parameter of a modern 
pharmaceutical formulation as it is the value that determines the efficacy of the 
product. Modified release formulations that are preferred nowadays by patients and 
prescribers are designed to provide a dissolution profile tailored to fit disease and 
patient characteristics, thus the factors influencing dissolution are of particular 
importance in their case. Our work attempts to investigate some properties of a model 
pellet formulation that potentially influence dissolution and translate the findings into 
a deeper understanding of the internal affairs of modified release multiparticulates. 
2. Current state of the art 
2.1. The production of multilayered pellets 
Multiparticulate drug delivery systems consist of many individual drug-
containing units as opposed to a single drug carrier entity. These units are typically 
spherical pellets between 100-2000 μm [1] that are further processed into capsules, 
tablets or dedicated pediatric dosage forms [2-3]. The concurrent use of pellet 
fractions with different APIs, drug contents, release properties, etc. offers a very wide 
range of possibilities for drug development. Multiparticulate drug delivery systems 
are also gaining popularity as their nature provides several benefits over single-unit 
dosage forms [4-5]. These include but are not limited to a lower irritative effect due to 
the decreased local concentration, less individual differences in plasma concentration, 
a reduced risk of dose dumping, improved bioavailability, a decreased variation 
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between doses, an easy solution for interactions and a large scale of dosage forms that 
can be produced from one intermediate [6-8].  
Pellets are good candidates for the development of multiparticulate dosage 
forms: they are small, spherical and smooth, therefore possess exceptional flow 
properties and processibility, especially in coating operations [9-10].  
Pellets can be produced by extrusion and spheronization or in a rotary fluid 
bed (matrix pellets) and by the so-called layering technique (layered pellets) [11-12]. 
The latter technique uses API-containing or inert (generally sugar or MCC) cores and 
processes them further, typically in a fluid bed equipment [11-12], where the materials 
of the next layer are sprayed onto the cores either as a (generally aqueous) solution, 
suspension or as dry powder [9, 13-14]. Layers typically contain one or more polymer 
components as binder [15]. Pellets retain their shape and flowability after layering. 
A critical parameter in suspension and powder layering is the particle size of 
the dispersion or powder. Achieving the smooth surface required for further 
processing and avoiding the abrasion and porosity issues generally calls for 
micronized substances where particle size has to be cross-referenced with the size of 
the cores used for production [15-16]. 
2.2. Processing in fluid bed equipment 
Fluidized bed systems have been widely used not only in the production of 
pellets but for drying and granulation as well. Regardless of purpose the system 
contains a (usually conical) chamber in which the solids used in the process are 
suspended in the so-called fluid state by the heated air flow blowing upwards. This 
constant movement and heating makes the equipment ideal for very quick drying. 
Main disadvantages are the large number of critical parameters that need to be 
monitored, multiple-step manufacturing, high production costs, greater need of 
excipients and advanced technological and human requirements [8, 17]. As pellet size 
affects the movement patterns of the fluidized solids a wide size distribution (or a 
badly picked narrow one) can also cause several problems during processing. 
The schematic drawings of three fluid bed set-ups are shown in Fig. 1. The 
first drawing depicts a top-spray equipment that is typically used for the granulation 
of powders. The second one shows a bottom-spray fluid bed coated equipped with a 
so-called Wurster column. The third picture is of a tangential spray or rotary fluid bed 
equipment (described in detail in [18]).  
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Figure 1: Schematic drawing of common fluid bed types; from left to right top spray, 
bottom spray with Wurster insert, tangential spray. Figure taken from [19], courtesy of 
Glatt 
Besides the auxiliary systems providing the fluidizing and spraying abilities all 
three have in common the cone-shaped expansion chamber where the air flow loses 
some of its velocity, the perforated plate at the bottom of the chamber regulating the 
air flow and the filters placed at the top of the chamber to prevent solids from 
escaping with the air flow [19]. 
The bottom-spray system with the Wurster insert is the optimal the equipment 
for coating processes [20]. The Wurster column partitions the expansion chamber into 
two main sections: due to the faster air flow provided by the air distribution plate at 
the bottom of the chamber particles move upwards inside the Wurster column (and get 
sprayed during the process) and slowly fall down around the insert due to the more 
gentle air flow around the perimeter of the partition. Particles are then sucked back 
into the Wurster column through the gap (the so-called partition height) between the 
bottom of the insert and the perforated plate by the pressure gradient maintained by 
the air velocity difference [21-22]. 
During a coating or layering process the wetting and drying of the particles are 
in a delicate balance that has a great impact on the final quality of the product [23]. 
The system is mainly defined by its drying capacity [24-25]. In the case of fluid beds 
the critical parameters that mainly determine drying capacity are inlet air temperature 
and volume. (Inlet air humidity is also a critical factor playing part but not all 
equipment – including both fluid beds used in this work – contains dehumidification 
pieces to be able to control this parameter.) Spray rate is limited by the drying 
capacity as too high rates will lead to particle agglomeration [26].  
Droplet size of the sprayed substance is determined by nozzle diameter and 
atomizing air pressure [27] but is also affected by the viscosity of the sprayed solution 
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or suspension. Suboptimal droplet size affects the quality of the product by either 
overwetting the particles (and thus facilitating their agglomeration) or spray drying 
where only the freshly dried solid content reaches the particles resulting in a rough 
and abrasive surface. 
Inlet air temperature and spray rate together determine product temperature 
which is often difficult to monitor inside the equipment. Product temperature must be 
chosen according to the thermal behavior of the materials involved in the process: low 
enough so as not to introduce degradation and high enough to provide for reasonable 
process durations [19]. 
Inlet air volume or more accurately inlet air velocity is also a key factor 
through maintaining a higher humidity gradient between the drying air flow and the 
particles. Fluidization patterns are governed by inlet air velocity therefore the 
movement of the particle bed can be optimized through this parameter. Too high 
velocity causes the particles to get stuck in the filter while too low velocity results in 
overwetting and agglomeration. The air distributor plate is also very important in 
determining fluidization patterns by distributing the air evenly thereby providing good 
gas-solid mixing and drying and minimizing dead zones and channeling [28]. 
Spray rate has to be chosen according to the factors described above. It is the 
most critical factor in determining process time and as such the maximal spray rate by 
which good product quality can be maintained can be considered the optimal choice. 
2.3. Film coating in fluid beds 
Coating is often the final step in the preparation of a multilayered pellet. As 
pellets are usually processed further into a dosage form that is more convenient to 
handle for the patient the coatings in question are usually functional. This means that 
their quality is of utmost importance in achieving the desired release profile and 
therapeutic response. 
Functional coatings can be categorized according to the release profile they 
convey. The most common ones are sustained release and delayed release but by 
combining polymers of different characteristics and suitable excipients a multitude of 
other release profiles become available [29]. 
Film coating was traditionally done by spraying an organic (or rarely aqueous) 
solution of the coating polymer on the core materials but due to toxicity and 
environmental concerns aqueous dispersions have become the standard solution [30]. 
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Dry powder coating – similarly to powder layering - involves the spraying of 
plasticizer solution although solutions without the use of any kind of solvent have 
been described [31-32].  
Coatings obtained through these three methods are drastically different both in 
quality [33] and in the method of formation. In an aqueous or organic solution the 
coating polymer chains are swollen and the single chains overlap. Upon solvent 
evaporation this degree of chain mixing remains and a uniform film is formed [34]. 
Aqueous dispersions contain the polymer in the solid state in globular form. 
Polymer chains in this state mainly form secondary connections within the molecule 
and do not interact with each other. Thus upon evaporation individual polymer grains 
remain, ideally densely packed on the cores’ surface. The evaporation of the water 
contained in the capillaries between the grains lead to particle deformation and under 
certain conditions film formation through coalescence of the polymer particles [35-
36]. Polymer dispersions exhibit a so-called minimum film forming temperature 
below which coalescence does not take place [37]; suspension coatings performed 
under the minimal film forming temperature of the polymer result in coatings that do 
not fulfill their intended role in esthetics, taste masking or controlling drug release. 
For most polymers plasticizers are required to reach a sufficient molecular mobility to 
achieve coalescence [38-39]. 
In the case of dry powder coatings the small amounts of liquid used in the 
process are generally not enough to facilitate film formation even with sufficient 
heating. Thus a curing step is required post-production, where the coated particles are 
heated above the glass transition temperature (Tg) of the coating polymer [40-41]. 
Above glass transition temperature polymer films transform from glassy to rubbery 
state where molecular mobility is enhanced and viscosity is decreased. This state can 
permit polymer particles to coalesce even without the aid of capillary forces but 
usually elevated humidity is employed during the process. 
As even in a glassy state polymers essentially behave similar to a very high-
viscosity liquid [41-42] coalescence can occur over long term storage. Uncoalesced or 
poorly coalesced films are porous and as such do not perform as well as coalesced 
films in dissolution tests therefore the slow coalescence over the lifetime of the 
product brings with itself a change in the dissolution characteristics that must be 
avoided at all costs [43]. Curing of the films helps achieving complete continuity and 
stability of the coatings and equalizes any potential differences in film structure. 
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Beside film structure film thickness has been identified as a critical parameter in 
the performance of functional coatings [44-45]. Many different techniques have been 
found suitable for the determination of film thickness with each one having distinct 
advantages and disadvantages over the others. For the direct measurement of the film 
thickness image analysis is the most common technique but recently tomographic 
methods have also gained recognition. Traditional static image analysis in the case of 
pellets is very labor-intensive especially in the case of scanning electron microscopic 
images where cross-sections are needed [46]. It is mostly for this reason that there is 
no agreement in the literature about a generally acceptable sample size that can 
accurately represent the whole batch [10, 47]. Computerized image analysis has been 
investigated as a tool to solve this problem but the skills needed for its application 
limit its usefulness. Also, both software and operator choice has been shown to 
influence results [48-49]. 
Dynamic image analysis is an emerging technique that specializes in the size 
range of most multiparticulate products. It alleviates the work load associated with 
image analysis and provides a more comprehensive view of particle properties but it 
usually requires the purchase of an expensive piece of equipment and (mainly due to 
the method making it possible to measure such amounts) requires a large amount of 
sample compared to the usually investigated quantity [50]. In both cases problems 
associated with particle projection and image focusing are present, and in addition 
dynamic image analysis may suffer from the difference between the calibration and 
the measurement method as well [51]. 
Raman and NIR spectroscopic methods have been proven to work both offline 
and inline [52-54] however these methods need to be calibrated to another (preferably 
direct) method and they rely on either a small sample or a multitude of particles 
averaged by their constant movement during processing. This means that while 
spectroscopic methods are a good general indicator of film thickness they cannot be 
relied upon when predicting the chance of product failure due to variations in coating 
thickness (for example on tablet edges). 
Tomographic methods are mostly absent of the above-mentioned disadvantages. 
In order to fully benefit from their advantages however samples need to be turned and 
repeatedly measured. Also some studies found that their detection limit was higher 
than for other methods investigated [55-57]. 
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The most traditional method of describing and reproducing film thickness 
however is through polymer weight gain [58]. While probably the easiest to measure 
polymer weight gain suffers from the same problems as spectroscopic methods. In 
addition it does not consider the unevenness and abrasion of the cores during the 
coating process or the deviations from the average weight gain which have been 
proven to crop up due to fluidized bed coating [46, 59-60]. As such polymer weigh 
gain is a questionable indicator of film thickness and dissolution behavior at best. 
The reasons for deviations from the average have been attributed to several 
different factors. In the easiest approach larger particles will receive a thicker coating 
because of their larger specific surface area. Several studies have found however that 
when normalizing polymer weight gain to specific surface area larger particles still 
received a larger amount of coating than smaller cores [22, 61]. 
These further differences are most commonly believed to stem from either the 
number or the efficiency of passes through the spray zone [22, 46] – unfortunately 
both of these factors require complicated experimental setups to investigate. They are 
strongly correlated to particle movement patterns that are governed by the previously 
described process parameters [23, 62]. Even in a narrow size distribution particle 
properties contribute a lot to the variation in the fluidization patterns and thus 
significant differences in coating levels can be detected [22]. Several mathematical 
models were developed using different approaches to the coating process, for example 
by considering the fluid bed equipment as a series of compartments [63] or by the 
Monte Carlo method [64]. By their probabilistic nature these models are more 
descriptive than predictive and do not include all parameters that can affect coating 
quality and uniformity. However models usually agree that longer coating times result 
in a more uniform distribution and that the main contributor to the coating variation is 
the non-uniform weight gain per pass through the spray zone [65]. 
2.4. Composition-related factors affecting dissolution 
Dissolution of coated dosage forms is affected by many factors. The most 
obvious one is the nature of the polymer coating: does it dissolve at a physiological 
pH, how permeable is it, what are its swelling and erosion characteristics? Traditional 
dosage forms usually exhibit a fast initial dissolution however where a coating was 
used to delay or retard dissolution at least the first phase of drug release will be 
characterized by diffusion through a (preferably intact) polymer film. An excellent 
7 
 
 
overview of the possible mechanisms governing this phase was presented by A.G.. 
Ozturk et al. [66]. 
Beyond the thickness and quality of the polymer film the excipients used in the 
coating can also have a great impact on the dissolution behavior. The most common 
types of excipients are plasticizers (especially important in aqueous coating 
operations), anti-tacking agents and dyes or pigments. 
Plasticizers are necessary for coating from aqueous dispersions as they facilitate 
the mobility of the polymer chains and as such help in forming a uniform film coat 
[67]. Different plasticizers work differently on the molecular level [68-69] and as such 
a generalized approach is difficult to maintain. However several plasticizers have 
been found to influence (generally increase) dissolution through evaporation or 
leaching (and consequentially pore formation [70-71] or in the unlikely cases where 
they form a continuous phase through dissolving the API and thus facilitating 
diffusion through the film [72]. Some studies have found that higher plasticizer levels 
resulted in a decreased drug release [73-74] which was attributed to insufficient 
plasticization and thus incomplete film formation at lower levels [66]. 
The coated substrate composition (and excipients not present in the sample but 
used in the production process [75] also have an impact on dissolution properties [76]. 
Several studies have found that release rate increases with solubility [45, 77-78] 
although some exceptions have been reported but mainly attributed to other factors 
[45, 79]. Beyond API-solubility the effects of different core materials through osmotic 
pressure or adsorption have been recently investigated by several authors [80-82] 
although conflicting results have arisen due to the water counter-current formed due 
to high osmotic pressure [83]. 
Binders like HPMC can also affect dissolution due to their dissolution-
enhancing properties found in other technological processes but very few studies have 
been conducted in this direction [12, 15]. Polymers frequently used as binders have 
been shown to improve solubility and dissolution rate through wettability [84] and 
prevent the recrystallization of amorphous drugs [85]. Core shape, size and surface 
have also been investigated and it was suggested that these parameters are just as 
important as the coating process itself when determining dissolution of the final, 
coated product [60, 86]. 
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3. Aims 
Pellets are an increasingly popular choice in the development of drug delivery 
systems, yet comparatively few studies deal with their investigation even by methods 
routinely used elsewhere in the pharmaceutical industry. Our aim was to study the use 
of different analytical techniques in the investigation of different characteristics and 
phenomena influencing dissolution, develop new ones and determine the extent of 
usefulness of methods that, given their nature and required circumstances, appear to 
have a limited applicability on pellets. 
The first section of this work describes the development of a Raman 
spectroscopic method for the determination of the film thickness of pyridoxine 
hydrochloride-containing coated pellets. Two different equipment set-ups were used 
for sample production and their impact on the outcome of the analysis was examined.  
Section two deals with the investigation of an atypical thermal phenomenon 
observed in diltiazem hydrochloride-containing multilayer pellets. This is divided into 
two larger parts: the investigation of the thermal behavior and the underlying 
recrystallization phenomenon and the development of a method to determine degree 
of crystallinity in intact pellets. 
4. Materials 
4.1. Raw materials 
Diltiazem hydrochloride (Ph. Eur., a gift from EGIS Ltd., Budapest, Hungary) 
and pyridoxine hydrochloride (Ph. Eur.) were used as model drugs, Cellet 500 (Shin-
Etsu Chemical Co., Ltd., Tokyo, Japan, granted as a gift from Harke Pharma) as 
nonpareil core material, Kollidon 25 (polyvinylpyrrolidone; BASF, Ludwigshafen, 
Germany) and Pharmacoat 606 (hypromellose; BASF, Ludwigshafen, Germany) was 
applied as a binder in the layering of the APIs, and Acryl-EZE (Colorcon, Dartford 
Kent, UK), a fully formulated enteric coating dispersion a methacryic acid copolymer, 
was used as coating material. 
4.2. Samples 
Samples’ names consist of two or three letters and two numerical characters. 
The first letter represents the API contained in the sample where 
D – indicates diltiazem hydrochloride 
P – indicates pyridoxine hydrochloride. 
The second letter indicates the binder used for the production of the sample such that 
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K – stands for Kollidon 25 
P – stands for Pharmacoat 606. 
In the case of samples labeled PP the third, additional letter represents the place of 
production where 
S – is for Szeged, Hungary 
D – is for Düsseldorf, Germany. 
The first number will either be 0 or 1 which indicates the lack of or presence of 
coating. The second numerical character is the batch number. 
5. Methods 
5.1. Preparation of samples 
The multiparticulate pellet samples were prepared in a Strea-1 (Niro Aeromatic, 
Bubendorf, Switzerland) fluid bed chamber. In the first, drug-loading step, API was 
layered onto nonpareil Cellet 500 cores. A solution of diltiazem hydrochloride or 
pyridoxine hydrochloride as API and Kollidon 25 or Pharmacoat 606 as binder in a 
mass ratio of 5:3 for Kollidon 25 and 5:2 for Pharmacoat 606 respectively was used. A 
batch size of 200 g of nonpareils and the above-mentioned solution containing 125 g 
of API was used. Water content of the solution varied with API solubility.  
Between drug-loading and coating the pellets were dried in the spray coater for 
10 minutes. Since the Acryl-EZE contains sodium bicarbonate as an excipient, the 
equipment was disassembled and washed to prevent precipitate formation. Samples of 
the drug-loaded nonpareils were taken for comparison purposes.  
In the second, coating step, a 20% aqueous dispersion of Acryl-EZE (a fully 
formulated USP copolymer type C coating system containing 60% polymer and 
various excipients) was prepared and applied as per the guidelines of the 
manufacturer. 0.1% of dimeticone was added to prevent foaming during the stirring 
and coating process. The parameters of the coating were the same as for the drug 
layering step in all cases. Samples of different coating levels were produced. 
5.2. Measurement of layer thickness 
An image analysis method (Leica Quantimet 500 MC, Leica Cambride Ltd, 
Cambridge, UK) was used to determine the thickness of the layers on the pellets. 
Particle size was specified as the average of the minimal and maximal diameter of the 
particle projection. The mean film thicknesses were calculated from the mean 
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diameters of the particles, determined by measuring 8 chords of approx. 300 particles 
of each batch with a stereomicroscope (Zeiss, Oberkochen, Germany). 
For the pyridoxine hydrochloride-containing samples three pellet batches from 
Düsseldorf and four batches from Szeged (pellets coated with Acryl-EZE® and 
uncoated pellets) were measured three times using the CamsizerXT image analysis 
system (Retsch® Technology GmbH, Haan, Germany, X-Fall module, free fall mode). 
The number of measured pellets per sample was counted during measurement. The 
value specifying the particle size is defined as width of the particle projection and is 
the shortest of measured maximum chords in 32 directions. The median of the number 
size distribution was used as the particle size of the sample. The coating thickness was 
calculated from the mean of n=3 measurements the half of the difference between the 
coated and uncoated diameter of the sample. 
5.3. Differential scanning calorimetry and thermogravimetric analysis 
Differential Scanning Calorimetry (DSC) was performed with a Mettler–Toledo 
DSC 821e (Mettler–Toledo GmbH, Switzerland) instrument. Thermogravimetric 
Analysis (TGA) was carried out with a Mettler–Toledo TGA/DSC1 (Mettler–Toledo 
GmbH, Switzerland) instrument. Sample weight varied between 10-12 mg for the TG 
measurements. Curves were evaluated with STARe Software. The starting 
temperatures were 0 °C for DSC and 25 °C for TG measurements respectively and 
heating rate was 10°C/min for most measurements. Final temperature varied 
according to the purpose of the measurement. Argon atmosphere was used in all 
cases. Three parallel examinations were done from all samples. The instrument was 
calibrated using indium. Samples were measured in a 40 μl aluminum pan. 
5.4. Powder X-ray diffractometry (XRPD)  
The X-ray powder diffraction patterns (XRPD) were obtained with a Brucker 
D8 Advance (Brucker AXS, Karlsruhe, Germany) that can be equipped with a Sycos 
H-Hot (Ansyco GmbH, Karlsruhe, Germany) programmable plate holder. Results 
were detected with a Våntec-1 detector. The patterns were recorded at a tube voltage 
of 40 kV, tube current of 40 mA, applying a step size of 0.01 Å 2θ in the angular 
range of 3 Å to 40 Å 2θ. 
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5.5. Hot-stage microscopy  
Thermomicroscopic investigations were carried out with a Nikon Michrophot 
FXA polarizing microscope (Nikon Corporation, Tokio, Japan) fitted with a Linkam 
THMSG-600 heating-freezing stage (Linkam Scientific Instruments, Waterfield, UK). 
Photographs were taken with a digital camera (UBS 2 UI-1640LE-C, IDS Imaging 
Development Systems GmbH, Obersulm, Germany). Pellets were carefully crushed 
and intact coating flakes chosen from the grist.  
5.6. Fourier-transformed infrared spectroscopy (FT-IR) 
FT-IR measurements were performed by an Avatar 330 FT-IR spectrometer 
(Thermo Nicolet/Thermo Fisher Scientific Inc., Ramsay, Minnesota, USA) equipped 
with a horizontal ATR crystal (ZnSe, 45°). Spectra were recorded between 4000 and 
400 cm−1 at 4 cm−1 optical resolution. Spectra were collected in absorbance mode 
using the KBr disk method (~0.5 mg powdered sample in 150 mg KBr disk). 256 
scans were co-added. Spectra were collected with the EZ Omnic software and 
analyzed with GRAMS/AI 9.0.  
5.7. Dissolution studies  
Drug content determination was done with a UV-VIS spectrophotometer 
(Unicam Helios α, Thermo Fisher Scientific Inc., Waltham, USA) at pH 6.8 
(phosphate buffer) from approx. 500 mg of whole pellets after two hours at 325.0 nm 
for pyridoxine hydrochloride and 237.0 nm for diltiazem hydrochloride with a 
bandwidth of 2 nm and a lamp charge of 325 nm. Coefficient of determination (R2) 
for the calibration curve was 0.9999 and 0.9983 respectively. 
Dissolution studies were carried out according to the Ph. Eur. standards with a 
rotating basket (Erweka DT 700, Erweka GmbH, Heusenstramm, Germany), in 900 
ml of simulated gastric acid at 100 rpm at 37 °C for 2 h, then the acidic medium was 
replaced with 900 ml of phosphate buffer (pH=6.8) and the dissolution measured at 
the same parameters as above. Samples were taken of the gastric acid at 2 h and of the 
phosphate buffer at 5, 10, 15, 20, 30, 45, 60 and 90 min. Three parallel measurements 
were performed for each sample. 
Drug concentration was measured spectrophotometrically at 235 nm for 
diltiazem hydrochloride and 291.0 nm for pyridoxine hydrochloride in artificial 
gastric acid by comparison to a calibration curve with an R2 of 0.9946 and 0.9996 
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respectively. For the measurements in artificial intestinal fluid the parameters and 
calibration curves were the same as described for the drug content determination. 
Results were analyzed with Microsoft Excel 2007. 
5.8. Raman spectroscopy  
The Raman spectra were measured using a RamanRXN2 analyzer (Kaiser 
Optical Systems, Ann Arbor, USA) with a non-contact optic sampling device (PhAT 
probe). The probe beam was generated using a diode laser operating at 785 nm and 
the laser power at the sample was 400 mW. The laser spot diameter was 6 mm 
corresponding to a 28.3 mm2 circular illumination area. Each sample was measured 
three times with an exposure time of 10 seconds and the average of the three spectra 
was used for further analysis. Data collection and Pearson’s correction were done 
using icRaman data collection software package (Kaiser Optical Systems, Ann Arbor, 
USA). 
5.9. Data analysis 
Savitzky-Golay smoothing (15 point, 2nd order polynomial), single normal 
variate (SNV) correction, principal component analysis (PCA) and partial least 
squares regression (PLS) were performed using Matlab 7.13.0.564 and the Statistic 
Toolbox. As Matlab utilizes the SVD algorithm for multivariate analysis while 
SIMCA-P, the software used to gather the results published in our article [87] uses the 
NIPALS algorithm results of the two calculations are not going to produce exact 
matches (they are however expected to provide the same conclusions). 
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6. Results and discussion 
6.1. Section I – Pellets containing pyridoxine hydrochloride 
6.1.1. Preparation of samples 
Preformulation studies began using Kollidon 25 as a binder as described in the 
Methods section. We found that during API layering this composition resulted in the 
extreme electrostatic charging of the cores that prevented the circulation of the 
material. Optimization of the parameters yielded little results so Pharmacoat 606 was 
used instead of Kollidon 25 in further experiments. No significant agglomeration 
tendencies were observed for either composition. 
Samples have been prepared in two different Strea 1 equipment pieces in the 
same batch sizes. The main differences between the two equipment were the use of 
the Wurster insert and the geometry of the column. The stainless steel column was set 
up to include the Raman probe described in the Methods section for inline 
measurements. The yield of the processes done with the Wurster insert was 
significantly higher than but further analysis showed no differences between the 
qualities of the samples that could not be traced back to production yields. 
Table 1: Layering and coating parameters 
 Strea 1 in Szeged Strea 1 in Düsseldorf 
Inlet temperature 50 °C 50 °C 
Outlet temperature 43 °C 37 °C 
Spray rate 6 ml/min 6 ml/min 
Air volume 80 m3/h (variable) 130 m3/h (pre-set) 
Nozzle diameter 1 mm 1 mm 
Chamber material Glass Stainless steel 
Wurster insert Yes No 
Spraying 
installation Bottom-spray Bottom-spray 
We have found that while fan capacity and fluid feed rate were critical 
parameters to the process not optimizing them for the different pieces of equipment 
only affected the yield of the production and not the quality of the samples. Yield was 
significantly higher in the Wurster equipment with values of 98-99% for API layering 
and 96-98% for coating. The lower values of 92-95% for API layering and 91-94% 
for coating observed in the bottom-spray equipment are most probably aggravated by 
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the difference in chamber geometry: the shape of the stainless steel chamber results in 
more collisions between particles and with the chamber wall [88].  
6.1.2. Determination of drug content and film thickness 
6.1.2.1. Particle size and film thickness 
Pyridoxine-containing samples were measured with the Camsizer and the 
Leica equipment as described in the Methods section. Results are summarized in 
Table 2. It is very important to note that the standard deviations shown in the table are 
different for the two measurement methods: SD for the Camsizer method is the SD of 
three measurements of the same sample between measurements while the SD of the 
Leica method was calculated from individual particle sizes within one measurement. 
Particle size and film thickness results between the two analytical methods 
show a fairly consistent behavior: while film thickness results can be said to be more 
or less equivalent between the two methods the mean particle sizes are usually larger 
when measured with the Leica equipment (and this difference is consistent between 
coated and uncoated samples as evident from the film thickness results). This is most 
probably explained by the different nature of the equipment: the Leica equipment 
employs a stereomicroscope focused on the stationary particles where the shadow cast 
by the particles distorts the image. The magnitude of the distortion also depends on 
the image recognition software and the resolution of the images taken of the particles. 
The Camsizer technology measures the shadow cast by the particles thus the 
distorting effects are taken into account during the calibration process.  
The only exception from this is Sample PPD12 that gave a larger film 
thickness result on the Leica equipment than with the Camsizer method. The 
diameters of the coated sample match our expectations based on the film thickness 
obtained with the Camsizer method and the diameters of Samples PPD11 and PPD13 
measured on the Leica equipment which means that the difference must stem from the 
measurement of the uncoated sample. Photographs taken of the particles during the 
Leica measurement (Figure 2) show that Sample PPD02 contains a much larger 
amount of fragmented particles than Samples PPD01 and PPD03. As the Camsizer is 
designed to measure large numbers of particles through obtaining 60 high-resolution 
images per second the statistical significance of the results obtained by it is much 
better ensured both for individual particles and for the whole batch than in the case of 
the Leica equipment. 
Table 2: Particle size and film thickness results of image analysis by Camsizer and Leica equipment 
Sample 
Amount of 
coating 
dispersion 
used for 
sample (g) 
Camsizer analysis results (µm) Leica analysis results (µm) 
Diameter of 
uncoated 
pellets 
Diameter of 
coated pellets
Coating 
thickness
Minimum 
diameter of 
uncoated 
pellets 
Minimum 
diameter of 
coated 
pellets 
 
Maximum 
diameter of 
uncoated 
pellets 
 
Maximum 
diameter of 
coated pellets 
 
Leica 
coating 
thickness 
Sample 
PPS11 300 718.27±0.11 788.93±0.25 35.33 731.78±37.91 803.63±48.64 793.04±43.83 861.74±67.65 
35.13 
Sample 
PPS12 450 695.13±0.31 781.43±0.06 43.15 707.41±65.92 795.11±42.47 764.27±58.30 857.69±46.86 
45.28 
Sample 
PPS13 500 722.00±0.10 823.33±0.15 50.67 742.12±53.71 847.61±42.69 802.47±42.59 907.71±50.85 
52.71 
Sample 
PPS14 600 695.87±0.06 813.00±0.00 58.57 706.83±38.28 836.15±41.49 769.50±48.04 892.08±45.07 
62.97 
Sample 
PPD11 300 721.03±0.06 774.80±0.17 26.88 716.04±35.80 773.61±34.21 783.18±41.72 834.92±40.31 
27.33 
Sample 
PPD12 450 721.17±0.12 798.43±0.06 38.63 703.73±32.41 806.50±30.17 771.52±33.90 872.02±37.78 
50.82 
Sample 
PPD13 600 724.73±0.15 821.37±0.06 48.32 727.12±34.85 823.52±38.31 789.73±40.63 890.84±59.30 
49.38 
16 
 
 
As the parameters for the production of all PDD samples were the same we 
regarded the anomalous result as a probable sampling error. 
The Camsizer film thickness results that were used in further studies show a 
linear correlation with coating polymer weight gain for pooled data (R2=0.9219). 
 
Figure 2: Leica microscopic image of Sample PPD02 
6.1.2.2. Dissolution 
The dissolution curves of the two sample sets are shown in Fig. 3. All samples 
showed a complete API release after 60 min in the pH 6.8 dissolution medium. 
Gastroresistance of the film coatings showed a relationship with their thickness where 
higher coating levels yielded better (in this case lower) results. 
Similar levels of coating showed similar levels of dissolution regardless of 
which equipment was used for sample production, indicating that the coating quality 
produced in different equipment (but with the same parameters) does not differ in this 
respect. Coatings of 35 μm or thinner were insufficient in achieving the Ph. Eur. 
requirements of gastroresistant films. The dissolution testing of Sample PPD11 was 
discontinued after observing over 50% drug release in artificial gastric acid. 
The possibility of a linear correlation was observed between the percent of 
drug dissolved in gastric acid and the film thickness was examined but the coefficient 
of determination (R2) has proven to be poor (0.6667). 
After excluding the data point from the discontinued dissolution test of Sample 
PPD11 however the goodness of fit improved to R2=0.8798 (see Fig. 4). Correlation 
between polymer weight gain and dissolution in artificial gastric acid yielded an R2 of 
0.6842 even after excluding the clearly outlying data point, suggesting that polymer 
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weight gain is a bad indicator of dissolution results even though it is a good predictor 
of film thickness [57]. 
 
 Figure 3: Dissolution of Sample sets PPS1 and PPD1 
 
Figure 4: Correlation of film thickness and dissolution is gastric acid; line fitted with 
the first data point excluded 
These results suggest that for gastroresistant films the prediction of dissolution 
performance based on film thickness measurements may be possible above a 
threshold value. In the case of the samples used for the study this threshold value is 
higher than the Ph. Eur. maximum requirement which means that the minimum film 
thickness can be safely estimated from the correlation. 
6.1.2.3. Raman spectroscopy 
The Raman spectra of the materials can be seen on Fig 5. The Acryl-EZE film 
coating system has peaks at 638 cm-1, 515 cm-1 and 395 cm-1 (henceforth referred to 
as Peak 1, Peak 2 and Peak 3) that are characteristic of the anatase polymorph of 
titanium dioxide [89]. These do not overlap with the largest characteristic peaks of 
pyridoxine hydrochloride which are at 1645 cm-1, 1629 cm-1, 1359 cm-1, 1233 cm-1, 
692 cm-1 and 329 cm-1 [90]. Both API and film coating peaks can be distinctly 
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observed in the spectra of the samples while signal from the polymer binder and 
cellulose core cannot be readily identified. 
 
Figure 5: Raman spectra of components 
 Baseline correction was done with the algorithm described by Pearson [91] 
that is included in the icRaman software to strip the spectra of the distorting effects of 
baseline shifts and fluorescence [92]. Peak heights were used for further study to 
minimize the uncertainty arising from the overlapping smaller peaks. 
 Univariate analysis of the titanium dioxide peaks showed all three to be good 
predictors of film thickness where a linear correlation existed between peak area and 
height and film thickness calculated from the Camsizer analysis results (Fig. 6. a). 
However this was only true when examining the two sample sets separately – neither 
sets fit into the others’ trend line. 
 For both sample sets the best fit could be obtained for Peak 1. Peak 2 and Peak 
3 gave reasonably good fits for Sample set PPS1 but showed a decreasing trend in the 
R2 value for both sets. Unlike Peak 2 and Peak 3 Peak 1 does not overlap with some 
characteristic peaks of pyridoxine hydrochloride which – probably being the reason 
for its better fit – makes it ideal for the univariate determination of film thickness.  
The peaks at 692 cm-1, 1233 cm-1, 1629 cm-1 and 1645 cm-1 corresponding to 
pyridoxine hydrochloride provided good correlations with the calculated API content 
(Fig 6. b,) – this was expected due to the attenuation of the API signals being 
dependent on the film thickness [93]. 
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Figure 6. a, Correlation between film thickness and titanium dioxide’s Raman peaks 
 
 
 
Figure 6. b, Correlation between calculated API content and the API’s Raman peaks 
The peaks between 1500 cm-1 and 1250 cm-1 have demonstrated worse results 
which is probably the result of the baseline correction being insufficient in this 
spectral region. It can be seen that the regression lines for both film thickness and API 
content are fairly parallel which means the degree of attenuation is consistent between 
the two sample sets. 
Comparing the raw spectra of the two data sets a trend becomes clearly 
visible: background fluorescence decreases with the film thickness for both sample 
sets.  An opposite phenomenon was observed for tablets by Kauffman et al. [93] 
where linear relationship was postulated between the degree of fluorescence 
stemming from the coating and film thickness. Romero-Torres et al. have also 
reported small baseline differences in coated tablets [94]; while in their case no 
systematic pattern was discernible, the effect of incomplete film coverage in thin 
coatings on highly fluorescent cores they described coincides with our observations of 
the dissolution and the baseline of Sample PPD11.   
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Figure 7: Raw Raman spectra of the coated samples 
 
Figure 8: Raw Raman spectra of the uncoated samples 
In our case the attenuation of the signal from the highly fluorescent API-
layered core can explain the negative trend. Sample set PPD1 appears to have a 
distinctively larger offset (see Fig. 7) in all cases. 
As long as the detection range is not exceeded fluorescence should not distort 
the Raman signal [93] but signal-to-noise ratio has been known to influence the 
efficiency of background subtraction techniques [92]. Other baseline correction 
methods such as SNV or MSC correction may result in a unified univariate model. 
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We should keep in mind that peaks indicating coating level are actually caused 
by the white pigment titanium dioxide and not the coating polymer itself. The closest 
direct indication of the coating polymer in the spectra would be the fluorescent shift 
most polymers possess [95] but as the formulation contains several other ingredients 
showing fluorescence differences in the baseline should be treated very carefully in 
this case. A look at the raw uncorrected spectra (Fig 8) shows that the systematic 
difference in the background already exists in the uncoated samples. 
While fluorescence is usually treated as problematic noise this systematic 
variation between the two sample sets suggests that further research might turn up 
interesting results. Raman spectroscopy has been shown to be suitable to differentiate 
between tablets coated under different conditions by Cahyadi et al. [96] and our 
results give a good indication of the same ability in pellets, however for a definitive 
conclusion further experiments would be needed. 
Principal component analysis of the raw spectra showed that 99.85% of the 
variation between the spectra is explained by the first principal component (PC) 
which resembles the baseline structure – as expected considering the nature of the 
calculations involved. Samples are ordered by set along the first PC with Sample set 
PPD1 showing positive and Sample set PPS1 showing negative values and samples of 
both sets are in decreasing order of film thickness (see Fig. 9).  
 
Figure 9. Scores plot of the principal components of raw Raman spectra 
For the multivariate analysis spectra were SNV corrected and principal 
component analysis was performed to observe the variation between the peak 
structures not confounded by baseline and scaling differences. PLS regression was 
performed to find a common calibration curve. SNV correction eliminates the basis of 
the original first PC by subtracting the baseline and normalizing the spectra thereby 
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providing a better chance to see the latent structures of the peaks. The first PC 
acquired from this analysis greatly resembles the Raman spectrum of titanium dioxide 
and corresponds to 91.44% of the variation between the spectra after SNV correction 
(see Fig. 10. a,). The second PC is very similar to the spectrum of pyridoxine 
hydrochloride with a small negative trace of the 638.1 cm-1 peak of titanium dioxide. 
This PC explains 6.03% of the variations. The scores plot (Fig. 10. b,) shows that 
samples are located in order of increasing film thickness along the first PC axis. 
These results show that pre-treatment can have a profound effect on the 
outcome of the analysis. According to the scree plot of the analysis (not shown) two 
PLS-components were found to give the best results based on the SNV-corrected 
spectra without signs of overfitting with 97.4% of the spectral variation and 98.61% 
of the film thickness variation explained. 
 
Figure 10: a, Loadings plot of the principal components of corrected Raman spectra 
 
Figure 10. b, Scores plot of the principal components of corrected Raman spectra 
The first component again resembles the Raman spectrum of titanium dioxide 
(see Fig. 11. a). This component is responsible for 91.43% and 96.36% of the X- and 
Y-directional variations respectively, indicating that the use of just this component can 
result in a reasonably good model. The second PLS-component contains only 5.94% 
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of spectral variation and is responsible for 2.25% of the variation in film thickness. 
The loadings of this component correspond to the Raman spectrum of pyridoxine 
hydrochloride in the negative. The two PLS-components indicate that the samples 
contain inversely proportional amounts of coating and API – ideally only one 
significant PLS-component would be enough to describe such a system. 
   
Figure 11: a, Loadings plot of the PLS components of the corrected Raman spectra 
 
Figure 11. b, Scores plot of the PLS components of the corrected Raman spectra 
Our final model included two PLS-components and provided a root mean 
square error of calibration (RMSEC) of 1.15 and a root mean square error of cross-
validation (RMSECV) of 2.29 using the leave-one-out method. The slope and y-
intercept of the linear fit also indicate the validity of the model (see Fig. 12). It is 
worth to mention that using only the first PLS-component in the model also results in 
a good correlation with an R2 of 0.9636 but the inclusion of the second component 
further reduces the mean square error of the leave-one-out cross-validation somewhat. 
The lasers utilized for Raman spectroscopy have small sampling area and 
penetration depth [97]. In our case the illumination area was 28.3 mm2, which means 
that, calculating with the smallest size, less than 100 pellets were measured in every 
case. This is a significantly lower number of pellets than what the literature generally 
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suggests [10, 47] and much less than the amount of particles measured with the 
Camsizer for the development of the method. Nevertheless, Raman spectroscopic data 
fit well the film thickness data, which in turn showed a linear correlation with the 
polymer weight gain. 
 
 
 
 
Figure 12: Linear model of the film thickness based on the PLS regression of the 
SNV-corrected Raman spectra 
Contrary to previous studies done on sustained release systems where film 
thickness was a good predictor of dissolution [51, 57] delayed release coatings appear 
to be more complicated. Our results suggest that there might be a threshold value 
above which a correlation exists. One of the reasons for this may be incomplete film 
formation. The greater mechanical stress the samples suffered in the bottom spray 
equipment could also have contributed to the poor dissolution performance through 
the formation of cracks and chips, which in the case of thin coatings (in this case 
Sample PPD11) could affect the preparation more adversely than in thick coatings. 
6.1.3. Summary 
A Raman spectroscopic method was developed to assess film thickness 
prepared in two different types of fluid bed equipment. In the dissolution tests no 
indication of the films formed in the two equipment being different in quality were 
observed, however circumstances of preparation and Raman spectroscopic results 
suggest that differences may exist on some level. Multivariate analysis has visualized 
this as a difference in the slope of the baseline. Results suggest that above a threshold 
value the results of a dissolution test may be estimated by the measurement of the 
coating thickness in gastroresistant pellets. 
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6.2. Section II – Pellets containing diltiazem hydrochloride 
6.2.1. Preparation of samples 
Diltiazem hydrochloride, being more water-soluble than pyridoxine 
hydrochloride, could be used in larger concentrations during API layering to reduce 
loading time. This meant however that the viscosity of the Pharmacoat 606 – 
diltiazem hydrochloride solution was so high that spraying became very cumbersome. 
To reduce viscosity Kollidon 25 was used for some of the samples. The loading 
parameters were: inlet temperature 50 °C, outlet temperature 43 °C, fan capacity 4.5, 
peristaltic pump speed 4 ml/min, air volume 75 m³/h, blow-out pressure 4.4 bar, 
atomizing pressure 2 bar and nozzle diameter 1 mm for drug layering and coating. 
In both compositions agglomeration was observed during API layering and 
coating. Fluid feed rate appeared to be the most important parameters that could 
influence agglomeration tendencies. Agglomeration was observed regardless of how 
low the fluid feed rate was but with discontinuous spraying the agglomerates broke 
down shortly after the spraying process was paused [76, 98]. This method has caused 
the coating time to stretch longer than expected. Higher fluid feed rates resulted in a 
large agglomerate blocking the Wurster insert so the experiment was discontinued. 
6.2.2. Determination of film thickness 
Film thickness was measured with the Leica equipment using the method 
described and examined in the previous section. Obtained values are summarized in 
Table 3.  
Table 3: Film thickness values of diltiazem hydrochloride-containing pellets 
Samples Coating dispersion (g) Film thickness (mean; μm) 
Sample DK11 300 15.5 
Sample DK12 300 17.7 
Sample DK13 400 23.5 
Sample DK14 500 28.9 
Sample DK15 600 44.4 
6.2.3. Study of the API migration and recrystallization 
6.2.3.1. Thermal analysis 
The DSC curves of the materials are presented in Fig. 13. The endothermic 
peak at ~220°C indicates the melting of diltiazem hydrochloride; the second, broad 
endothermic peak on the curve can be attributed to API degradation. The broad 
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endothermic peaks on the curves of Kollidon 25 and Pharmacoat 606 are related to the 
water loss of the polymers. No glass transition temperature could be determined 
which is probably due to it being obscured by the water loss peak and the changing 
plasticity caused by the water loss. The Tg of Acryl-EZE is visible at ~60°C, but no 
peaks characteristic of the excipients used in its composition appear on the curve. 
 
Figure 13: DSC curves of the raw materials 
As shown in Fig. 14, the melting point of diltiazem hydrochloride appearing in 
all the samples has shifted to about 10°C lower than observed in its pure form and an 
exothermic peak appeared at about 100°C on the DSC curves of the coated pellets. 
The Tg of Acryl-EZE did not shift significantly and the Tg of the binder polymers did 
not appear on the curves. 
 
Figure 14: DSC curves of some samples containing diltiazem hydrochloride 
The peak at 100°C showed up only in samples containing both diltiazem 
hydrochloride and the Acryl-EZE coating (see Fig. 15), which suggests that it is a 
result of an interaction between these two materials. According to its manual Acryl-
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EZE contains sodium bicarbonate as an excipient, which precipitates diltiazem base 
from the aqueous solution of diltiazem hydrochloride [99]. (This concurs well with 
our previous experience where the same reaction made it necessary to disassemble 
and wash the equipment between API layering and coating.)  
 
Figure 15: Effect of sample compositions on the DSC curves 
The melting point of diltiazem base is in the same thermal range as the 
exothermic peak, however no melting point appears on the curves in this range and a 
thermally undetectable amount of sodium bicarbonate does not seem likely to produce 
detectable amounts of diltiazem base in the first place.  
Fig. 15 shows that a similar exothermic peak appeared at about 180°C or 
directly before the melting point on the curves of the uncoated pellets where no 
sodium bicarbonate was present in the preparation. This peak is very apparent in the 
HPMC (Pharmacoat 606)-containing sample and much less present in PVP-containing 
ones, in come cases it is even completely missing. 
 An amorphous sample of diltiazem HCl was prepared by quench cooling to 
measure the Tg which proved to be at 100°C (Fig. 16). The repeated heating of Sample 
DK14 also plotted on the same figure showed that the exothermic peak appears only 
during the first heating cycle.  
Fig. 17 shows that a slow weight loss starts approximately at 50°C that 
accelerates slightly at about 100°C for the uncoated sample. In the case of the coated 
sample water loss starts much later. Total weight loss up to 100°C is only a few 
percent in all cases; this concurs with the water loss of the polymers described before 
and explains why the effect is delayed in coated samples where much of the water is 
contained beneath the coating. The samples begin to lose weight fast above the 
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melting point of diltiazem HCl which again concurs with our knowledge of the 
composition. 
 
Figure 16: Thermal behavior of amorphous diltiazem hydrochloride 
 
Figure 17: Weight loss of coated and uncoated samples 
6.2.3.2. X-ray analysis 
As shown in Fig. 18 the XRPD diffractogram of diltiazem HCl comprises 
several peaks; the larger ones that can also be seen in the samples’ diffractograms are 
at 4.125°, 8.328°, 9.907°, 10.547°, 18.070°, 19.442°, 21.661° and 27.575° 2θ. Cellet 
500, Kollidon 25 and Pharmacoat 606 are either polymeric or microcrystalline; hence 
only very broad peaks appear in their diffractograms which do not hinder the 
identification of the sharp peaks from other materials. Talc, listed as an ingredient of 
Acryl-EZE by the manufacturer, produced the two sharp peaks visible in the 
diffractogram of the coating system.  
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Figure 18: X-ray diffractograms of raw materials 
The XRPD diffractograms were detected at room temperature at baseline and 
heated to 120°C and to 200°C afterward. Results are presented in Fig. 19. The 
diffractogram of every coated sample shows a sharp peak at 25.648° 2θ. This was 
identified as titanium dioxide [100], used as white pigment in the Acryl-EZE coating 
system. The diffractograms of Kollidon-containing samples indicate the presence of 
crystalline API at baseline while Pharmacoat-containing samples seem to be missing 
the peaks characteristic of the API indicating that it is in amorphous form. 
In all cases diltiazem hydrochloride peaks have become larger (or, in some 
cases, appeared) after heat treatment. In the case of uncoated samples API peaks 
appeared/grew only after heat treatment at 200°C whereas coated samples 
demonstrated the same recrystallization after being heated to 120°C. Comparing 
120°C and 200°C heat treated (coated) sample spectra a decrease in API peak heights 
can be seen which is probably due to the decomposition of diltiazem hydrochloride. 
The nature of the sample preparation process closely resembles the procedures 
employed during the solvent method of the preparation of solid dispersions. This 
implies that a solid dispersion can be formed during API layering that, depending on 
the composition and parameters, can contain the API in any and all physical forms 
[19, 101]. X-ray analysis revealed that the occurrence causing the exothermic peak at 
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~100ºC is recrystallization of the API. In the uncoated samples amorphous API 
recrystallizes only upon or close to melting (see Fig. 19. b,). 
 
 Figure 19. a, X-ray diffractograms of coated samples at different temperatures 
 
Figure 19. b, X-ray diffractograms of uncoated samples at different temperatures 
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6.2.3.3. FT-IR analysis 
The FT-IR spectra of a Kollidon-containing coated sample before and after 
recrystallization upon heating are shown in Fig. 20. a. Both the samples and the 
physical mixture of binder and API exhibit a water peak at 3450 cm-1, although the 
water content of the sample appears to have significantly decreased heat treatment. In 
the un-treated sample several peaks are less prominent (if visible at all) and wider, 
less sharp than in the physical mixture. No shifts in peak positions occurred indicating 
that no chemical bonds formed between API and polymers. The spectrum of the heat 
treated sample is mostly the same as that of the physical mixture; slight differences 
can be attributed to the presence of other excipients. FT-IR spectra of a Pharmacoat 
606-containing sample have yielded similar results (see Fig. 20. b,).  
6.2.3.4. Hot-stage microscopy 
The polarized light microphotograph of a piece of coating (Fig. 21) taken 
using crossed Nicol prisms shows that the polymeric film layer contains crystalline 
material even before heat treatment (left side). After the heat treatment (right side) the 
amount of birefringent particles in the coating increased which indicate that the 
crystalline material is diltiazem hydrochloride. 
The API migrated into the coating and part of it remained amorphous that later 
crystallized upon heat treatment. The probable mechanism of migration is that the 
highly water-soluble diltiazem hydrochloride dissolved into the droplets of coating 
suspension hitting the surface of the API-layered cores during the coating process 
[102-103]. The plasticization mechanism described by Mizuno et al. can also play a 
role in the process [104]. Binder polymers might also play a part by improving the 
speed of dissolution even further by forming solid dispersions with the API upon 
layering [101, 105-107]. This hypothesis is supported by Fig. 15 (see page 35), which 
shows that no exothermic peak appears on the DSC curves of a coated sample 
prepared without binder.  
Migration probably occurs mostly before a uniform coating layer forms on the 
drug-loaded cores [104] and thus affects only a small fraction of the API. Considering 
the fact that the drug layer already contains an amorphous fraction (see Fig. 15 where 
recrystallization can be seen in the uncoated samples close to the melting point of 
diltiazem hydrochloride), migration does not explain the difference in the 
recrystallization behavior of the coated and uncoated samples.  
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 Figure 20. a: FT-IR spectra of interaction between API and Kollidon 25 
 
Figure 20 b: FT-IR spectra of interaction between API and Pharmacoat 606 
As no chemical bonds between polymer and API were found in either case it 
can only be physical inhibition that prevents the drug from completely crystallizing 
during sample preparation and storage [85, 106]. In such cases the main reason of 
recrystallization is the glassy to rubbery state transition of the API-containing polymer 
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and the increased molecular mobility of the API that is the result of the increased 
mobility of the polymer chain segments separating the API clusters [105-106]. It has 
been described by several authors that the physical stability of a drug depends greatly 
on the preparation method and the polymer carrier [108-110]. In our case the methods 
of preparation were the same for all samples but the API (both amorphous and 
crystalline fractions) is split between the coating layer and the drug layer, which 
means that based on the above theory we should observe two phases in the 
recrystallization: one for the drug layer and one for the coating (or only one 
overlapping one). However, only one recrystallization phase was observed which 
appeared at significantly lower temperatures in coated samples than in uncoated ones. 
 
Figure 21: Coating fragment under the polarized light microscope before and after 
heat treatment 
This discrepancy must be explained by the presence of the coating. The DSC 
curves of the uncoated samples contain a broad endothermic peak that literature 
attributes to the loss of water in the binder polymers. This peak does not show up on 
the curves of coated samples and the TG curves indicate that water loss in the coated 
samples starts close to the boiling point indicating a watertight property of the coating 
at least on the timescale of the DSC analysis. The exothermic peak attributed to API 
recrystallization is in the thermal range of the boiling point of water. This raises the 
question: can water play a role in the recrystallization behavior of the API [111]? 
Several theories postulated by other authors can be used to explain the 
possible influence of water on the behavior of our coated samples [112-113]. Many 
studies proved that water can act as a plasticizer in polymers; as such it can decrease 
the Tg of the polymer to the thermal range of our exothermic peak – which it cannot 
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do for the uncoated samples as most of the water evaporates by the time the sample 
reaches the temperature range in question [114]. Water can also be trapped in the 
pores of the microcrystalline cellulose core after API layering. Diltiazem 
hydrochloride, being highly water-soluble, can dissolve in the water migrating toward 
the surface of the pellet from the core and crystallize with the eventual evaporation of 
the solvent. As water boils in the thermal range of the recrystallization peak, the 
pressure of the forming steam in the pores of the pellet is expected to grow rapidly at 
the time of the event. As described before, water also acts as a plasticizer, so pores can 
be easily expanded by the steam essentially removing the physical barriers in the 
polymer structure that stood in the way of recrystallization. This expansion process is 
well-known in the food industry (a good description can be found in articles detailing 
the making of popcorn [115-116]) but a similar effect was noted during the use of 
supercritical or pressurized carbon dioxide in the pharmaceutical industry [117-119]. 
6.2.3.5. Stability 
These mechanisms can and in reality probably do work independently from 
each other at the same time. This presents problems regarding the stability testing of 
samples of this nature. Studies should take into consideration that the high relative 
humidity used in accelerated stability testing could cause recrystallization by 
plasticizing the polymer that would not happen under ambient conditions [113, 120]. 
To compensate for this effect samples were stored at 40˚C at 70% relative humidity, at 
40˚C in a low humidity environment (25±5%), at 75±5% relative humidity at room 
temperature (20˚C±2˚C) and at ambient conditions (45±5% and 20˚C±2˚C). 
Fully amorphous samples have fully recrystallized after a day at both highly 
humid conditions while samples stored at lower humidity levels remained fully 
amorphous until the closing of the experiment 50 days later. This concurs well with 
the results of Zelkó et al. [121] where they have demonstrated that only high humidity 
values cause a change in the structure of PVP. 
A study at elevated humidity was conducted to investigate the kinetics of the 
recrystallization in coated samples. Samples have recrystallized slowly at start but 
recrystallization speed increased greatly after a lag time (see Fig. 22) that can 
correspond both to film thickness and initial degree of crystallinity. 
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Figure 22: Recrystallization trends as indicated by XRPD peak 9.907° 2θ 
The former was confirmed by a water uptake study where samples of equal 
volume were stored in open containers in a closed hygrostat containing distilled water 
on ambient temperature. Samples were weighted at regular intervals and the results 
plotted in Microsoft Excel. 
 Uncoated samples exhibited an exponentially decreasing water uptake. Coated 
samples initially showed linear water uptake that gradually slowed when approaching 
saturation concentration. This concurs with the equation used to describe diffusion-
regulated dissolution from coated pellets [122-123]. Linear trend lines considering the 
zero intercept were fitted to the data and rate constants calculated for the coated 
pellets. Rate constants showed a strong inverse relationship with the film thickness 
with the coefficient of determination being reduced by the fact that Samples DK11 and 
DK12 are very close in coating thickness. 
 
Figure 23. DSC curves of coated and uncoated samples at slow heating rate 
The direction of diffusion is determined by the concentration gradient which 
means that the equations generally used to describe dissolution behavior can be used 
to describe material influx governed by diffusion. The trends observed for water 
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uptake will by the same logic be true for loss of water too. This corresponds well with 
the differences between the weight loss patterns of coated and uncoated samples we 
have seen during the thermogravimetric measurements. To evaluate the role of water 
loss in recrystallization a TG-DSC experiment with a low heating rate was performed. 
The 1°C/min heating rate was expected to provide enough time for the 
evaporated water to diffuse through the coating thereby equalizing the water loss 
trend with that of the uncoated pellets. As can be seen in Fig. 23 DSC curves have 
both fulfilled that expectation: weight loss rates were even between coated and 
uncoated samples with only a slight delay for the coated pellets and recrystallization 
occurs in both coated samples in the same thermal range as in their uncoated 
counterparts. This confirms that the fast evaporation of water played a crucial part in 
causing the difference in recrystallization behavior. 
6.2.3.6. Dissolution studies 
As expected, dissolution in artificial gastric acid is inversely correlated to film 
thickness with 23.5 μm film thickness already achieving sufficient gastroresistance for 
Sample set DK. As the extent of API migration was not determined in the study no 
further conclusions can be drawn from the results. 
Problems similar to the ones described in the section on stability arise when 
trying to determine the significance of recrystallization on the dissolution behavior. As 
intentional recrystallization without the destruction of the sample involves heat 
treatment, it is logical to assume that curing of the coating also takes place during the 
process which would improve the outcome of a later dissolution test [43, 114, 124]. 
Also if the pores expand significantly enough in volume the coating polymer would 
either rupture [125] or, what is more probable given that it is in rubbery state at the 
temperatures involved, would stretch thinner (thus decreasing its performance) and 
transform back into the glassy state upon cooling. The extent of API migration and the 
starting film thickness would probably also influence the results. 
While results in gastric acid improved significantly for Sample DK11 and 
DP12 the change observed in the case of Sample DK14 was well beneath the SD 
value of both tests. These results suggest that no rupturing occurred due to the heat 
treatment itself which means that heating the samples did not result in significant 
volume expansion. Overall no clear trend could be seen in the direction of the 
changes.  
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6.2.4. Measurement of the degree of crystallinity 
Six sub-samples were taken from Samples DK01-5 and their X-ray 
diffractograms collected. Diffractograms were then used to attempt to set up a 
calibration curve for the determination of the degree of crystallinity based on ssNMR 
results. 
6.2.4.1. ssNMR 
Spray drying techniques are substantially impacted by environmental factors 
and as such are hard to control regarding the solid state of the product [126]. To obtain 
an absolute value of the degree of API crystallinity of the samples solid phase NMR 
measurements were performed using the CP-MAS technique with a 13C-1H coupling.  
Table 4: Degree of API crystallinity measured with ssNMR (increasing order) 
Sample Degree of crystallinity of the API (%) 
Sample DK03 11 
Sample DK01 23 
Sample DK05 35 
Sample DK02 49 
Sample DK04 49 
6.2.4.2. X-ray characterization of samples 
Pellet formulations were expected to cause difficulties with the measurements 
due to their size and shape. Packing in the traditional sense of the phrase is less likely 
to occur as a problem but considerable noise and peak shifting are to be expected due 
to the air pockets between the particles. Uneven surface and sample displacement 
cause peak broadening and peak shifting when using Bragg-Brentano equipment 
[127]; with intact pellets neither can be avoided during measurement. Peak intensity 
also decreases in rough surfaces compared to smooth ones. When analyzing 
multilayer pellets starting material concentrations in the focusing circle are not 
necessarily the same as in the sample bulk due to the different composition of the 
layers of the sample and are hard to determine because of the unknown but 
presumably small penetration depth [128-129]. Solid dispersions also have a tendency 
of exhibiting changes in halo shape and intensity [130] and anisotropic peak shifting 
has also been observed [131]. Because of these effects whole-pattern fitting and 
pattern subtraction techniques [132] are very likely to fail. On the other hand pellets 
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usually have a narrow size distribution, meaning that these features are likely to be 
fairly consistent between samples. This probably reduces the confounding effects to a 
level that still makes the analysis of intact pellets possible.  
Preferred orientation effects have been known to appear in intact 
pharmaceutical dosage forms [133-134]. In the case of pellets prepared by solution 
layering the preference of some directions during crystal growth is likely to be 
balanced in the three-dimensional space. Nevertheless, samples were rotated during 
measurement to reduce any possible effects. 
A diffractogram of Sample DK01 representative of most diffractograms 
obtained from Samples DK01-5 was shown in Fig. 19. b. Sample DK03 turned out to 
be X-ray amorphous but the diffractogram showed no new halo features that could be 
definitively attributed to amorphous diltiazem hydrochloride. This can be a result of 
the halos of the polymer components overlapping over most of the 2θ range or 
differences in the intensity and concentration of the materials. In this case most 
probably both of these effects occur. Characteristic peaks of diltiazem hydrochloride 
are shifted in sample diffractograms and the extent of the shift is not consistent for all 
peaks and samples. The excessive noise (although expected) made the results of any 
analysis so uncertain that smoothing had to be employed in order to continue [135]. 
The Savitzky-Golay smoothing algorithm was used with a frame width of 15 data 
points and a 2nd degree polynomial and diffractograms were normalized to unit area 
to compensate for weight differences. From here on peaks will be referred to as their 
maximum observed in pure diltiazem hydrochloride.  
6.2.4.3. Determination of the crystalline content by univariate methods 
Crystalline and amorphous intensities are proportionate to crystalline and 
amorphous concentrations [132]. The degree of crystallinity of the sample can be 
calculated as 
 [132] 
where Ic and Ia are usually area under the crystalline peaks and the halo respectively, 
but peak heights can also be used [130, 132]. The formula requires separation of the 
amorphous halo from the crystalline peaks. This is a procedure prone to errors [136] 
as is the definition of the baseline [137] that is required for calculations.  
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Preliminary calculations were performed to choose the best-performing peaks 
and also to determine which peak parameter to use for further calculations. The 
characteristic peaks at 9.907° 2θ, 10.547° 2θ, 18.071° 2θ, 19.442° 2θ, 20.521° 2θ and 
27.575° 2θ were chosen for their consistently good performance despite some 
troubling characteristics that shall be discussed later. 
Area methods generally provide better results than peak heights because of the 
wider 2θ range involved [134]. In our case however peak heights almost always 
provided better results than peak areas. The previously shown formula was used to 
calculate results from total area parameters. Predicted crystallinity was plotted against 
the theoretical crystallinity obtained from the ssNMR measurements. The 
mathematical values used to describe the linear fit are the slope and y-intercept, the 
coefficient of determination (R2) and the root mean square error of calibration and 
cross-validation. For the univariate regressions these have been calculated in 
Microsoft Excel and are summarized in Table 5. As ssNMR uses very small sample 
sizes compared to XRPD it is reasonable to assume that sampling errors are more 
likely to occur during the ssNMR measurement therefore the result may not 
necessarily be representative of the sample bulk. While the particles were mixed 
before sampling for XRPD measurements to reduce the chance of obtaining biased 
sub-samples the actual degree of crystallinity of the sub-samples can differ from each 
other and from the „theoretical value” for the samples obtained by ssNMR as flow 
properties and thus drying characteristics are inhomogeneous during production [138-
139]. Repeated ssNMR measurements would solve this issue but NMR measurements 
are both time-consuming and costly and therefore parallel measurements were not 
performed. 
Due to its largest relative intensity the 10.547° 2θ peak was deemed the most 
promising for quantitative analysis, however it provided the worst results of all the 
examined peaks. The amorphous halo shows steeply increasing intensity in the region 
of the 19.442° 2θ and 20.521° 2θ peaks which makes peak and halo separation and 
thus measurement of the peak parameters prone to errors [140]; in spite of this the 
peaks provided good linear fit and RMSECV. Considering the amorphous halo as seen 
on the diffractograms of Cellet 500 and Kollidon 25 it can be said that this is the only 
region in which the trends in the halo can be clearly identified which makes these 
peaks more suitable for analysis than similarly sized peaks in other regions.  
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The peak at 27.575° 2θ is a double peak of moderate intensity in the API 
diffractogram that fused into one broad peak in the sample diffractograms. Despite 
this less than ideal quality it showed a good predictive value. This possibly stems 
from the amorphous halo being fairly even and not very intensive in the region which 
probably makes peak and halo separation less error-prone. 
Baseline correction has resulted in significantly worse slope and R2 values 
although this time peaks generally provided better results in order of increasing 
intensity. This indicates that the definition of the baseline can influence the outcome 
of the analysis both adding to and compensating for errors from other sources. 
Some correlations showed signs of non-linearity; for this reason a log-
transformation was performed and calculations repeated. While R2, RMSEC and 
RMSECV values have improved in some cases slopes and y-intercepts show a larger 
deviation from the expected values of unity and zero respectively. R2 values still do 
not reach the generally acceptable level of 0.95 and bias toward the small peaks can 
still be observed. In general it can be said that the log-transformation worked best for 
the two smaller peaks examined and the area ratio but even in these cases linear fits 
clearly perform better in some areas. 
While promising, the overall results of the univariate analysis cannot be 
considered ideal or, in many cases, reliable based on the problems described above. 
Partial least squares regression was tested to overcome difficulties in parameter 
selection and to find a good fit based on not confounded information. 
Table 5: Regression results for Savitzky-Golay smoothed diffractograms 
Sum of 
peak 
heights 
Peak position (2θ) Crystalline/ 
 amorphous 
area ratio 
19.442
° 9.907° 10.547°
20.52
1° 
27.575
° 
Slope 1 1 1 1 1 1 1 
y intercept 2*10-5 8*10-5 5*10-5 1*10-4 1*10-4 3*10-5 3*10-5 
R2 0.881 0.9028 0.9165 0.8846 0.8972 0.9277 0.9173 
RMSEC 5.12 4.62 4.28 5.04 4.75 3.99 4.26 
RMSECV 5.38 4.86 4.52 5.29 5.00 4.20 4.51 
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6.2.4.4. Determination of the crystalline content by multivariate methods 
Multivariate analysis is a good technique to avoid the interference of 
excipients and random noise during quantitative analysis [141] especially in intact 
dosage forms [142]. First a principal component analysis was performed to see if the 
method could differentiate between samples. Three principal components were found 
relevant to the investigation which explained a total of 89.31% of the variation in the 
diffractograms (see Fig. 24. a,).  
 
Figure 24. a, Loadings plot of the principal components 
    
Figure 24. b-c, Scores plots of the principal components 
The first PC appears to contain shifts in the amorphous halo and the diltiazem 
hydrochloride peaks. The second PC very closely resembles the diffractogram of 
diltiazem hydrochloride. While the third PC resembles the second one it contains the 
indications and corrections for API peak shifts and an obviously larger amount of 
noise than the previous PCs. This indicates that while there is still about 11% of 
variation unaccounted for most of it is likely to be attributed to random noise. 
Score plots of the principal components (Fig. 24. b-c,) show that sub-samples 
are clearly clustered according to their source sample. As the source samples varied in 
crystallinity this gives us a good indication about the possible positive outcome of 
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further work. Samples are ordered along the second PC according to degree of 
crystallinity with the exception of Sample DK02 and DK05. 
  
Figure 25. a, Loading plot obtained from PLS-regression 
    
Figure 25. b-c, score plots obtained from PLS-regression 
PLS analysis also found three significant components that, while explaining 
89.25% of the spectral variation, correspond to 95.81% of the differences in the 
degree of crystallinity. PLS component weights for the first two components closely 
resemble the diltiazem hydrochloride diffractogram with the both components 
containing the amorphous halo from microcrystalline cellulose in negative and in 
positive respectively (see Fig. 25. a,). The broad microcrystalline cellulose feature and 
the baseline shift in the lower 2θ region appearing in the first two PLS-components 
are cancelled out or greatly reduced for most samples when considering both 
components indicating that they have little actual influence on the outcome variable. 
Exceptions are some sub-samples of Sample DK03 and Sample DK02 where this 
behavior can either signify an anomaly or unlucky sampling. In the case of the X-ray 
amorphous Sample DK02 this may be the result of the other features in the 
components needing to be zeroed. As a few sub-samples from less affected samples 
also contain the two components with opposing signs it is likely that the effect is due 
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to the innate variability of pellets within one sample; an obvious such characteristic 
would be particle size but more experiments are needed to show a definite connection. 
Score plots obtained for the PLS-components again show the same clustering 
as was described for PCA (see Fig. 25. b,). Samples are approximately in order of 
increasing degree of crystallinity along the first PLS-component axis. Samples DK02 
and DK05 are clearly set apart only by the third PLS-component (containing a halo 
feature and shifted API peaks among some noise) as seen in Fig. 25. c.  
The model obtained from the analysis shown in Fig. 26 supersedes all previous 
attempts to obtain a calibration curve with an RMSEC of 3.04 and an RMSECV of 
3.88. 
 
Figure 26. Linear model of the degree of crystallinity based on the PLS regression of 
the XRPD data of intact pellets 
These results have shown that the degree of API crystallinity of intact pellets 
can be examined by XRPD despite the initial difficulties. Univariate models varied in 
their predictive quality – often the best models came from the most dubious sources. 
PLS analysis provided better results and gave much less reason to worry about the 
validity of the obtained model. Building the PLS model was also less time-consuming 
due to the lack of preparatory work while for the univariate model not only the peak 
and halo separation needed to be done but also preliminary calculations were required 
to avoid choosing the most obvious but in reality not very predictive parameter. 
6.2.5. Summary 
In this section diltiazem hydrochloride-containing pellets were investigated to 
find the reason of an atypical behavior and its impact on stability testing and 
dissolution. We have also attempted to measure the degree of crystallinity of the 
uncoated samples from intact pellets with both univariate and multivariate methods. 
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7. Final conclusions, novelty, practical usefulness 
The influence of various factors and phenomena on the dissolution of enteric 
coated pellets was investigated in this study. Pellets were manufactured by solution 
layering in a fluidized bed and subsequently coated with a fully formulated enteric 
coating system. Two model APIs and two model hydrophilic binder polymers were 
used and the four possible compositions were analysed and their characteristics cross-
referenced to see the effect of composition, process parameters and other phenomena 
on the behavior of multilayer pellets. 
- API-layered and coated pellets were manufactured in fluid bed 
equipment in different compositions. Problems encountered during 
manufacturing were successfully solved and the transfer of the 
technology to a different device showed the procedure to be robust 
enough to withstand significant differences in manufacturing 
equipment. Through this we obtained a solid understanding of what 
the critical process and product parameters are. 
- Differences between the products stemming from the differences 
between the equipment were described and investigated. This 
information can be put to good use in the pharmaceutical industry 
where differences in the manufacturing equipment tend to cause 
problems during scale-up and technology transfer processes.  
- Two image analysis methods for the measurement of particle size 
were compared and evaluated. For the purpose of film thickness 
measurements the two methods gave similar results even though they 
differed substantially in the measurement of particle size 
characteristics. Results indicate that the automatized method using 
large sample sizes was more robust to sampling effects and sample 
characteristics. 
- Raman spectroscopy proved to be a good tool for the measurement of 
the film thickness of coated pellets. Multivariate data analysis made it 
possible to differentiate samples based on their preparation 
conditions. It was shown that while the configuration of the fluid bed 
used for sample preparation probably has an effect on the Raman 
signal this difference does not indicate a difference in the 
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performance of the coating. A relationship between film thickness and 
gastric resistance was postulated. 
- An unexpected change in thermal behavior due to the addition of a 
coating layer was investigated. The effect of API migration on 
dissolution was analysed and the representativeness of some stability 
testing procedures were evaluated. The existence of such phenomena 
and especially their ability to place limitations on standard evaluation 
procedures emphasizes the importance of understanding product 
behavior deeply enough to anticipate future problems – a goal that is 
pursued through similar means by the Quality by Design initiative. 
- A multivariate model was developed for the determination of the 
degree of API crystallinity from intact drug-layered pellets. 
- One of the main objectives of model development was to avoid 
complicated and time-consuming pre-treatment and analysis. The 
models and methods described in the work can be easily utilized at-
line or – under optimal circumstances – even in-line to follow the 
development of the product during the manufacturing process. By 
being able to monitor the changes in the product in real time these 
techniques can fulfill the needs of Process Analytical Technology. 
 
Part of the purpose of the study was to investigate the use of widespread 
analytical methods in the development of pellets. As multiunit systems are much less 
researched than traditional dosage forms analytical methods are not usually developed 
with the goal of making them easy and efficient to use in their development. Our 
results showed that nevertheless some tools primarily used in the development of 
other dosage forms can be efficiently employed for pellets if their unique nature is 
taken into consideration. 
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Abstract
Context: Although several methods have been investigated to measure the film thickness of
tablets and its correlation with the dissolution behavior, much fewer such investigations exist
for pharmaceutical pellets.
Objective: To study the possibility of measuring the film thickness and predicting the
dissolution behavior of pellets produced in different fluid bed equipments with Raman
spectroscopy.
Materials and methods: Pyridoxine hydrochloride-layered pellets were produced and coated
in two different Strea-1 equipments. Raman spectra were collected and analysed to set up a
calibration model based on the film thickness data calculated from Camsizer analysis results.
Dissolution tests were done according to Ph. Eur. standards.
Results: Raman spectroscopy proved to be a good tool in the measurement of film thickness.
Polymer weight gain showed a linear correlation with film thickness but was a poor predictor
of dissolution results below a threshold value.
Conclusion: The Raman spectroscopic measurement of a small sample can provide accurate
data of the film thickness. The investigation suggests that a threshold value might exist for the
film thickness above which it can be used to judge future dissolution results.
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Introduction
The use of pharmaceutical pellets provides numerous advantages
over single-unit dosage forms1–5. Among these is the smaller
variation of the in vivo dissolution profile which results in
predictible therapeutic effect. However, the multiparticulate
nature causes problems when determining coating thickness
which critically affects the drug release6. For the direct measure-
ment of film thickness, scanning electron microscopy was often
used, but usually a very low number of pellets was measured, and
the cross-section images require that the pellets be sliced which
makes the measurement very time-consuming7–9. Image analysis
can be used to measure a statistically significant number of pellets
but there is some disagreement on what this statistically
significant number may be. In addition, the methods used to
analyse the acquired images are often incomparable10,11. The use
of a Camsizer allows the rapid measurement of a large number
of particles making it ideal for the calibration of indirect methods
to measure film thickness12.
Weight gain as the most traditional indirect method has been
criticized for its lack of specificity stemming from the mass
loss of the core material and failure to predict dissolution
values13–15. Spectroscopic and tomographic methods have been
used recently to quantify the film thickness of pharmaceutical
preparations9,16–24. This study utilizes Raman spectroscopy which
has been demonstrated to be suitable for the offline and online
(not online in this study) measurement of the film thickness of
tablets23–25. Its use regarding pellets however appears to be much
more limited26.
In our work we examine pellets of the same composition
prepared in two different fluid bed equipments to determine
whether a multivariate calibration model that is feasible for the
determination of the coating thickness of samples prepared in
either equipment can be built.
Experimental section
Materials
Pyridoxine hydrochloride (Ph. Eur.) was used as a model drug.
Cellet 500 (Shin-Etsu Chemical Co., Ltd., Tokyo, Japan) was
used as non-pareil core material. Pharmacoat 606 (BASF,
Ludwigshafen, Germany) was applied as a binder. Acryl-EZE
(Colorcon, Dartford Kent, UK), a fully formulated enteric coating
dispersion was used as coating material.
Layering of pyridoxine hydrochloride
The pellet samples were prepared in a Strea-1 (Niro Aeromatic,
Bubendorf, Switzerland) fluid bed wurster chamber. Two differ-
ent pieces of equipment were used with slightly different
capabilities and chamber layouts (Table 1). As the chamber
Address for correspondence: Peter Kleinebudde, Institute of
Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University,
Universita¨tsstr. 1, D-40225 Du¨sseldorf, Germany. Tel: +49-211-81-
14220. Fax: +49-211-81-14251. E-mail: kleinebudde@hhu.de
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geometry of the Du¨sseldorf equipment is such that it prevents the
use of a Wurster, insert experiments in these cases were
performed using bottom-spray mode.
A solution of pyridoxine hydrochloride and Pharmacoat 606 in
5:2 mass ratio with a total solid content of 12.28% was sprayed
onto 200 g nonpareil cores (between 500 and 710mm in diameter
as specified by the manufacturer) until 175 g dry material was
applied. The pellets were dried in the spray coater for 10 min.
Coating of layered pellets
Acryl-EZE dispersion was prepared and applied following the
guidelines provided by the manufacturer as 20% aqueous
dispersion. The manufacturer lists the ingredients of the Acryl-
EZE ready-to-disperse fully formulated coating system as USP
type C methacrylic acid copolymer, sodium bicarbonate, talc,
SiO2, titanium dioxide, sodium laurylsulphate and triethyl citrate.
Only a small amount (0.1%) of dimeticone was added to prevent
foaming during the process. Samples were prepared with different
coating levels using the same equipment and parameters as for the
drug layering. In the two different equipments two sets of samples
were prepared. Four batches were made in one and three in the
other. The sets differ only in the equipment used for manufactur-
ing; samples within the set differ in coating levels (Table 2).
Measurement of particle size and film thickness
Three pellet batches from Du¨sseldorf and four batches from
Szeged (API-layered pellets coated with Acryl-EZE and
uncoated API-layered pellets) were measured three times using
the CamsizerXT image analysis system (Retsch Technology
GmbH, Haan, Germany, X-Fall module (free fall mode)). The
number of measured pellets per sample was counted during
measurement. Due to differences in the sampling method the size
of the samples varies thus the number of measured uncoated
pellets lies between 53 000 and 103 000 and the number of coated
pellets is between 35 000 and 62 000. The value specifying the
particle size is defined as the width of the particle projection and
is the shortest of measured maximum chords in 32 directions.
The median of the number size distribution was taken for further
evaluation. The coating thickness was calculated from the mean
of n¼ 3 measurements as follows:
A ¼ dmin coated pellets  dmin uncoated pellets
 
2
where A is the coating thickness (mm), dmin coated pellets is the
particle size of uncoated pellets (mm) (n¼ 3; mean) and dmin
uncoated pellets is the particle size of Acryl-EZE
 coated pellets
(mm) (n¼ 3; mean).
Drug content and dissolution
Drug content determination was done with a UV-Vis spectropho-
tometer at pH 6.8 (phosphate buffer) at 325.0 nm from approx.
500 mg of whole pellets after 2 h. R2 of the calibration curve is
0.9999. Dissolution studies were carried out according to Ph. Eur.
standards with a rotating basket (Erweka DT 700, Erweka GmbH,
Heusenstramm, Germany), in 900 ml of simulated gastric acid at
100 rpm at 37 C for 2 h, then the acidic medium was replaced
with 900 ml of phosphate buffer (pH¼ 6.8) and the dissolution
measured at the same parameters as above. Samples were taken of
the gastric acid at 2 h and of the phosphate buffer at 5, 10, 15, 20,
30, 45, 60 and 90 min. Concentration was measured with a
spectrophotometer (Unicam Helios a, Thermo Fisher Scientific
Inc., Waltham, MA) at 291.0 nm with an R2 of 0.9996 in artificial
gastric acid (pH 1.2). In the phosphate buffer, the same
parameters and calibration were used as for drug content
determination.
Raman and chemometric analysis
The Raman spectra were measured using a RamanRXN2 analyzer
(Kaiser Optical Systems, Ann Arbor, MI) with a non-contact optic
sampling device (PhAT probe). The probe beam was generated
using a diode laser operating at 785 nm and the laser power at the
sample was 400 mW. The laser spot diameter was 6 mm
corresponding to a 28.3 mm2 circular illumination area. Each
sample was measured with an exposure time of 10 s. Data
collection, calculations, mean centering of the entire dataset,
baseline correction (SNV, standard normal variate), spectral
comparison (PCA, principal component analysis) and the con-
struction of the predictive model (PLS regression, partial least
squares regression) were done using icRaman data collection
software package (Kaiser Optical Systems, Ann Arbor, MI),
SIMCA 13.0 (Umetrics, Umea, Sweden) and Excel (Version
2007, Microsoft Corporation, Redmond, WA).
Calibration and validation development
In order to detect the amount of enteric coating material
calibration was developed based on the offline results of two
coated pellet sets (n¼ 3þ 4). A multivariate model was built
based on the data sets and the results of the film thickness
measurement obtained by the CamsizerXT image analysis system
was used as reference analytical method.
Results
Particle size and film thickness
The pellets without the final enteric coating vary in size from
695mm to 725mm (Table 2) due to different thicknesses of the
pyridoxine hydrochloride layer. These uncoated API-layered
pellets show a standard deviation in particle size of 0.06–
0.31 mm (n¼ 3). The standard deviation in particle size of the
Acryl-EZE coated pellets (n¼ 3) varies between 0 and 0.25 mm.
Table 1. Process and equipment parameters.
Strea 1 in Szeged Strea 1 in Du¨sseldorf
Inlet temperature 50 C 50 C
Outlet temperature 43 C 37 C
Spray rate 6 ml/min 6 ml/min
Atomizing pressure 2 bar 2.2 bar
Air volume 80 m3/h 130 m3/h
Nozzle diameter 1 mm 1 mm
Chamber material Glass Stainless steel
Wurster insert Yes No
Spraying installation Bottom-spray Bottom-spray
Table 2. Particle size of uncoated and Acryl-EZE coated pellets (n¼ 3;
mean), calculated film thickness.
Sample
Particle size
of uncoated
pellets [mm]
(n¼ 3; mean)
Particle size of
Acryl-EZE
coated
pellets [mm]
(n¼ 3; mean)
Coating
thickness
[mm]
Polymer
weight
gain [g]
Set1 sample1 718.27 0.11 788.93 0.25 35.33 52.9
Set1 sample2 695.13 0.31 781.43 0.06 43.15 73.9
Set1 sample3 722.00 0.10 823.33 0.15 50.67 87.0
Set1 sample4 695.87 0.06 813.00 0.00 58.57 131.1
Set2 sample1 721.03 0.06 774.80 0.17 26.88 43.8
Set2 sample2 721.17 0.12 798.43 0.06 38.63 67.7
Set2 sample3 724.73 0.15 821.37 0.06 48.32 90.3
2 K. Nikowitz et al. Drug Dev Ind Pharm, Early Online: 1–6
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The coating thickness in sample set 2 increases in steps of almost
10mm per sample. The coating thickness of the samples in set 1
differs by 8 mm in the order of the numbering.
Drug content and dissolution
All samples released the API completely after 60 min in the pH
6.8 dissolution medium. Drug release in artificial gastric acid was
greatly influenced by the thickness of the film coating with higher
coating levels yielding better results. Similar levels of coating
showed similar gastric resistance regardless of the equipment used
for sample production, indicating that the quality of the coatings
produced in different equipments does not differ much in this
respect. Samples with a film thickness of 38 mm or above have
demonstrated dissolution values below 10% that satisfy the
requirements of gastroresistant films. The dissolution testing of
Set 2 sample 1 was discontinued after observing over 50% drug
release in artificial gastric acid (Figure 1).
Raman and chemometric analysis
A PLS predictive model was constructed using the SNV
normalized spectra data from the two sample sets with enteric
coating levels from 27 to 59 mm (Table 2).
Figure 2 shows the SNV preprocessed Raman spectra (n¼ 3;
mean) of pyridoxine HCl (ingredient of the first pellet layer),
Acryl-EZE (enteric coating material of the second pellet
layer) and two pellet sets with different enteric coating levels
(four batches produced in Szeged, three batches produced
in Duesseldorf) in a spectral range 150–1890 cm1. The spectra
comprised dominant Raman shifts of the first layering as well
as shifts of the final enteric coating. Pyridoxine HCl shows
characteristic Raman shifts (692 cm1, 1234 cm1) which can
be assigned to the quadrant stretching vibrations and the
deformation of the 3-Hydroxypiperidin ring according to Cita S
et al. (1999)27 (692 cm1 vvs: tors(C2-C3-C9-H19)þ stretch
quadrant (C2-C4-C5-N7)þ tors(C3-C2-C4-C5), 1234 cm1 vs:
(O–H); (N–H) i.p.). Acryl-EZE is a preformulated aqueous
acrylic coating containing the pigment TiO2 and Eudragit L100-
55 as enteric coating polymer28. Titanium dioxide can be used in
two different polymorphic forms in pharmaceutical formulations.
Figure 1. Dissolution of coated pellets (a) set 1 prepared in Szeged and (b) set 2 prepared in Du¨sseldorf, in order of increasing film thickness.
Figure 2. Standard normal variate (SNV) preprocessed Raman spectra
(n¼ 3; mean) of pyridoxine–HCl, Acryl-EZE and two pellet sets with
different enteric coating levels (n¼ 3þ 4), spectral range 150–
1890 cm1.
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The polymorphic form anatase used in this study shows intensive
Raman shifts (637 cm1, 513 cm1, 395 cm1). These shifts are
caused by the bending vibration and the symmetric stretching
vibration of the polymorph (636 cm1 vs: (TiO2); 513 cm
1 m:
(TiO2); 395 cm1 m: (TiO2))
29. The intensity of titanium
dioxide Raman shifts increases whereas the intensity of the
pyridoxine–HCl shifts decreases with the encreasing amount of
enteric coating material, clearly visible in the spectral range of
310–715 cm1 (Figure 3).
Principal component analysis (PCA) of the offline acquired
Raman spectra were performed to discriminate sample sets by
increasing mass of coating material. With the exception of data
point 2 and 3, PCA scores on the first principal component (PC1)
are able to order the samples with respect to the theoretical
amount of enteric coating along the first principal component
(Figure 4a). PC1 explains 91.4% of the variance. Loadings on PC1
mainly correspond to spectral information from the titanium
dioxide anatase polymorph in the Acryl-EZE layer (Figure 4b).
The construction of PC1 can therefore be explained by the
increasing amount of enteric coating material coated onto the
pyridoxine hydrochloride layered pellet core. In Figure 4(c), each
data point displays a sample with certain amount of Acryl-EZE
coating, which was measured by Raman spectroscopy and
analyzed by a PLS regression algorithm. The coating thickness
as predicted by the multivariate model derived from Raman
measurement is plotted against the corresponding data as obtained
by the CamsizerXT reference method. Best predictive results for
the PLS regression model were obtained by using three principal
components, which explain 100% of the X-Variance (spectral
data) and 98.7% of the Y-Variance (coated Acryl-Eze amount)
(Table 3). The high variances of the model indicate its validity
to predict the enteric coating level even though it was built on
Figure 3. Standard normal variate (SNV) preprocessed Raman spectra
(n¼ 3; mean) of two pellet sets with different enteric coating levels
(n¼ 3þ 4), spectral range 310–715 cm1, decreasing Raman shifts
(330 cm1, 692 cm1), increasing Raman shifts (395 cm1, 513 cm1,
637 cm1).
Figure 4. (a) Principal component analysis (PCA) scores plot obtained from SNV preprocessed Raman spectra (n¼ 3; mean), (b) p-loadings of PC1 of
the PCA model and (c) calibration variance regression model for SNV Raman spectra (PLS).
Table 3. Parameter set of the multivariate model30.
Model description Results
Regression algorithm PLS
Number of components 3
Calibration range 27–59mm
Range of wavenumbers 150–1890 cm1
R2X 1.000
R2Y 0.987
RMSEE 2.53mm
RMSEcv 3.44mm
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spectra which contains peaks of both pellet layers. The black
line represents the linear fit to the data points. The resulting R2
value of the regression line can be used to quantify the strength
of the association between the observed Y and the predicted Y
for the pellet samples. The closer the R2 value is to one the
stronger the association between the observed and the predicted
variables31. The predicted coated thicknesses obtained by the
multivariate model fits the real thicknesses measured by the
reference method with exception of datapoints 5 and 6 (sample 1
set 1, sample 3 set 2). This might be due to the small differences
in coating thickness (2.35 mm) between these two samples. The
data points 2 and 3 (sample 4 set 1, sample 2 set 2) showing
a coating thickness difference of 3.3 mm are also hard to classify.
This leads to the assumption that multivariate models in
combination with offline Raman analysis reaches a limit of
classification ability in samples which only differ slightly from
one another in coating thickness.
Discussion
According to Rantanen, one of the problems with Raman
spectroscopy is the small sampling area and penetration depth32.
In our study the illumination area was a 28.3 mm2 circle, which
means that, calculating with a single layer, less than 100 pellets
were measured with the Raman probe. This is a significantly
lower number of pellets than measured with the Camsizer, once
again raising the question of what minimal number of pellets is
capable of representing the whole batch regarding film thickness.
Nevertheless, Raman spectroscopic data is in good agreement
with the film thickness data acquired with digital image analysis,
which in turn shows a linear correlation with the polymer weight
gain. This again suggests that the structure of the film coatings
was not impacted significantly by the differences in the equipment
used for their preparation.
No direct linear correlation was observed for the percent
of drug dissolved in gastric acid. As can be seen in Figure 5
this is mainly due to the poor performance of Set 2 sample 1.
After excluding this data point from the dissolution results the
coefficient of determination improved to 0.8798 and 0.6842 for
correlation with film thickness and polymer weight gain respect-
ively. These findings correspond with those of Ho et al., whose
work showed that weight gain was a poor predictor of dissolution
values14.
Contrary to previous studies done on sustained release systems
where film thickness was a good predictor of dissolution14,33
delayed release coatings appear to be more complicated. Our
results suggest that there might be a threshold value above which
a correlation exists. One of the reasons for this may be incomplete
film formation. The greater mechanical stress the sample suffered
in the bottom spray equipment compared to the Wurster coater
could also have contributed to the poor dissolution performance
through the formation of cracks and chips, which in the case
of thin coatings (in this case sample 1 set 2) could affect the
preparation more adversely than in the case of thick coatings.
Conclusion
In this study a Raman spectroscopic model was built for the
measurement of the film thickness of pellets produced in different
equipments. Dissolution test results and the existence of a shared
film thickness–polymer weight gain correlation indicates that the
structure of the film was similar in the samples regardless of
which equipment was used for their preparation. Raman spec-
troscopy proved to be a good tool in measuring the film thickness.
Pellets with the lowest film thickness were not gastric resistant.
When excluding these pellets from the examination the correl-
ation between film thickness and dissolved fraction after 120 min
was good, leading to the hypothesis that a threshold value,
possibly representing the polymer film formation and integrity,
exists for the correlation to function. This threshold value cannot
be derived from spectral or film thickness data alone.
Declaration of interest
The publication is supported by DAAD-MOB/P-MOB/817 (Hungary) and
50430305 (Germany) and by the European Union and co-funded by the
European Social Fund. Project title: ‘‘Broadening the knowledge base and
supporting the long term professional sustainability of the Research
University Centre of Excellence at the University of Szeged by ensuring
the rising generation of excellent scientists.’’ Project number: TA´MOP-
4.2.2/B-10/1-2010-0012.
References
1. Bechgaard H, Hagermann NG. Controlled-release multi-units and
single unit doses. A literature review. Drug Dev Ind Pharm 1978;4:
53–67.
2. Bodmeier R. Tableting of coated pellets. Eur J Pharm Biopharm
1997;43:1–8.
3. Kra¨mer J, Blume H. Biopharmaceutical aspects of multiparticulates.
In: Ghebre-Sellassie I, ed. Multiparticulate oral drug delivery.
New York: Marcel Dekker Inc.; 1994:307–32.
4. Ghebre-Sellassie I. Pellets: a general overview. In: Ghebre-Sellassie
I, ed. Pharmaceutical pelletization technology. New York: Marcel
Dekker Inc.; 1989:1–13.
5. Ghebre-Sellassie I, Knoch A. Pelletization techniques. In: Swarbrick
J, Boylan JC, eds. Encyclopedia of pharmaceutical technology.
New York: Marcel Dekker Inc.; 2002:2067–80.
6. Haddish-Berhane N, Jeong SH, Haghighi K, Park K. Modelling
film-coat non-uniformity in polymer coated pellets: a stochastic
approach. Int J Pharm 2006;323:64–71.
7. Wesdyk R, Yoshi YM, Morris K, Newman A. The effect of size and
mass on the film thickness of beads coated in fluidized bed
equipment. Int J Pharm 1990;65:69–76.
8. Wesdyk R, Joshi YM, De Vincentis J, et al. Factors affecting
differences in film thickness of beads coated in fluidized bed units.
Int J Pharm 1993;93:101–9.
9. Andersson M, Holmquist B, Lindquist J, et al. Analysis of film
coating thickness and surface area of pharmaceutical pellets using
fluorescence microscopy and image analysis. J Pharm Biomed Anal
2000;22:325–39.
10. Larsen CC, Sonnergaard JM, Bertelsen P, Holm P. Validation of an
image analysis method for estimating coating thickness on pellets.
Eur J Pharm Sci 2003;18:191–6.
11. Podczeck F, Rahman SR, Newton JM. Evaluation of a standardised
procedure to assess the shape of pellets using image analysis. Int J
Pharm 1999;192:123–38.
12. Ho L, Cuppok Y, Muschert S, et al. Effects of film coating thickness
and drug layer uniformity on in vitro drug release from sustained-
release coated pellets: A case study using terahertz pulsed imaging.
Int J Pharm 2009;382:151–9.
13. Mozˇina M, Tomazˇevicˇ D, Lebe S, et al. Digital imaging as a process
analytical technology tool for fluid-bed pellet coating process.
Eur J Pharm Sci 2010;41:156–62.
Figure 5. Correlation of film thickness and dissolution in gastric acid
after 120 min.
DOI: 10.3109/03639045.2013.795583 Raman measurement of the film thickness of pellets 5
D
ru
g 
D
ev
el
op
m
en
t a
nd
 In
du
str
ia
l P
ha
rm
ac
y 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f S
ze
ge
d 
on
 0
5/
15
/1
3
Fo
r p
er
so
na
l u
se
 o
nl
y.
14. Ho L, Mu¨ller R, Gordon KC, et al. Applications of terahertz pulsed
imaging to sustained-release tablet film coating quality assessment
and dissolution performance. J Control Release 2008;127:79–87.
15. Ho L, Mu¨ller R, Gordon KC, et al. Terahertz pulsed imaging as an
analytical tool for sustained-release tablet film coating. Eur J Pharm
Biopharm 2009;71:117–23.
16. Lee M-J, Seo D-Y, Lee H-E, et al. Inline NIR quantification of film
thickness on pharmaceutical pellets during a fluid bed coating
process. Int J Pharm 2011;403:66–72.
17. Mu¨ller J, Brock D, Knop K, et al. Prediction of dissolution time and
coating thickness of sustained release formulations using Raman
spectroscopy and terahertz pulsed imaging. Eur J Pharm Biopharm
2012;80:690–7.
18. Bikiaris D, Koutri I, Alexiadis D, et al. Real time and non-
destructive analysis of tablet coating thickness using acoustic
microscopy and infrared diffuse reflectance spectroscopy. Int J
Pharm 2012;438:33–44.
19. Ringqvist A, Taylor LS, Ekelund K, et al. Atomic force microscopy
analysis and confocal Raman microimaging of coated pellets. Int J
Pharm 2003;267:35–47.
20. Kauffman JF, Dellibovi M, Cunningham CR. Raman spectroscopy
of coated pharmaceutical tablets and physical models for multivari-
ate calibration to tablet coating thickness. J Pharm Biomed Anal
2007;43:39–48.
21. Koller DM, Hannesschla¨ger G, Leitner M, Khinast JG.
Non-destructive analysis of tablet coatings with optical coherence
tomography. Eur J Pharm Sci 2011;44:142–8.
22. Cahyadi C, Karande AD, Chan LW, Heng PWS. Comparative study
of non-destructive methods to quantify thickness of tablet coatings.
Int J Pharm 2010;398:39–49.
23. Romero-Torres S, Perez-Ramos JD, Morris KR, Grant ER. Raman
spectroscopic measurement of tablet-to-tablet coating variability.
J Pharm Biomed Anal 2005;38:270–4.
24. Romero-Torres S, Perez-Ramos JD, Morris KR, Grant ER. Raman
spectroscopy for tablet coating thickness quantification and coating
characterization in the presence of strong fluorescent interference.
J Pharm Biomed Anal 2006;41:811–19.
25. Mu¨ller J, Knop K, Thies J, et al. Feasability of Raman
spectroscopy as PAT tool in active coating. Drug Dev Ind Pharm
2010;36:234–43.
26. Sova´ny T, Nikowitz K, Regdon Jr G, et al. Raman spectroscopic
investigation of film thickness. Polym Test 2009;28:770–2.
27. Cita S, Morari C, Vogel E, Maniu D. Vibrational studies of B6
vitamin. Vib Spectrosc 1999;19:329–34.
28. Colorcon. Acryl-EZE Aqueous Acrylic Enteric System.
Available from: http://www.colorcon.com/products/coatings/
enteric-delayed-release/acryl-eze [last accessed 18 Nov 2012].
29. de Veij M, Vandenabeelen P, De Beer T. Reference database of
Raman spectra of pharmaceutical excipients. J Raman Spectrosc
2009;40:297–307.
30. Wirges M, Mu¨ller J, Kasa P. From mini to micro scale – Feasibility
of Raman spectroscopy as a Process Analytical Tool (PAT).
Pharmaceutics 2011;3:723–30.
31. Umetrics, Umea, Sweden. SIMCA Help. SIMCA 13.0 Software
package.
32. Rantanen J. Process analytical applications of Raman spectroscopy.
J Pharm Pharmacol 2007;59:171–7.
33. Heinicke G, Schwartz JB. Assessment of dynamic image analysis as
a surrogate dissolution test for a coated multiparticulate product.
Pharm Dev Technol 2006; 11:403–8.
6 K. Nikowitz et al. Drug Dev Ind Pharm, Early Online: 1–6
D
ru
g 
D
ev
el
op
m
en
t a
nd
 In
du
str
ia
l P
ha
rm
ac
y 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f S
ze
ge
d 
on
 0
5/
15
/1
3
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
 
 
 
 
II 
European Journal of Pharmaceutical Sciences 48 (2013) 563–571Contents lists available at SciVerse ScienceDirect
European Journal of Pharmaceutical Sciences
journal homepage: www.elsevier .com/ locate/e jpsStudy of the recrystallization in coated pellets – Effect of coating on API crystallinity
Krisztina Nikowitz, Klára Pintye-Hódi, Géza Regdon Jr. ⇑
Department of Pharmaceutical Technology, University of Szeged, H-6720 Szeged, Eötvös utca 6, Hungary
a r t i c l e i n f o a b s t r a c tArticle history:
Received 4 July 2012
Received in revised form 22 November 2012
Accepted 13 December 2012
Available online 2 January 2013
Keywords:
Pellet
Coating
Recrystallization
Diltiazem hydrochloride0928-0987/$ - see front matter  2012 Elsevier B.V. A
http://dx.doi.org/10.1016/j.ejps.2012.12.018
⇑ Corresponding author. Tel.: +36 62 545 574; fax:
E-mail address: geza.regdon@pharm.u-szeged.hu (Coated diltiazem hydrochloride-containing pellets were prepared using the solution layering technique.
Unusual thermal behavior was detected with differential scanning calorimetry (DSC) and its source was
determined using thermogravimetry (TG), X-ray powder diffraction (XRPD) and hot-stage microscopy.
The coated pellets contained diltiazem hydrochloride both in crystalline and amorphous form. Crystalli-
zation occurs on heat treatment causing an exothermic peak on the DSC curves that only appears in pel-
lets containing both diltiazem hydrochloride and the coating. Results indicate that the amorphous
fraction is situated in the coating layer. The migration of drugs into the coating layer can cause changes
in its degree of crystallinity. Polymeric coating materials should therefore be investigated as possible
crystallization inhibitors.
 2012 Elsevier B.V. All rights reserved.1. Introduction
Polymorphs and amorphous materials have generated a great
interest in the pharmaceutical industry, although processing and
stability issues such as phase transformations signiﬁcantly hinder
their application (Serajuddin, 1999; Zhu et al., 2010). In the case
of amorphous materials solid dispersions are the most commonly
used solution.
Solid dispersions can be prepared with several methods; the
two classical ones are melting and solvent evaporation (Leuner
and Dressman, 2000). Supercritical ﬂuid processing can also be
used as an alternative (Sethia and Squillant, 2004).
One version of the solvent evaporation method uses a ﬂuid bed
chamber to spray the solution of the drug and the carrier, generally
polymeric in nature, onto inert cores (Zhang et al., 2008; Sun et al.,
2008).
Multilayer pellets are produced in a very similar way. Inert cores
can be used in their preparation (Nastruzzi et al., 2000; Sinchaipa-
nid et al., 2004), and the same polymers are frequently used in their
production as binders and as coatings. The materials are sprayed
onto the cores in a ﬂuid bed chamber either as a (generally aqueous)
solution, suspension or as dry powder (Ghebre-Sellassie, 1989;
Singh et al., 1995; Vervaet et al., 1995). The polymer binders used
in the drug solution or suspension are generally evaluated for inter-
actions with the drug (Türk et al., 2009; Bonferoni et al., 2000).
Incompatibilities aside, coatings have not been widely studied
for their inﬂuence on the drug layer underneath, althoughmigration
of drugs into the coating layer has been described (Heinicke andll rights reserved.
+36 62 545 571.
G. Regdon Jr.).Schwartz, 2007;Wouessidjewe, 1997) and their chemical properties
can signiﬁcantly inﬂuence drug release (Sadeghi et al., 2003).
In our study we would like to show that when the solid phase
behavior of the drug is a factor, coatings must be taken into ac-
count. We have formulated a coated multilayer pellet containing
the model drug diltiazem hydrochloride in a ﬂuid bed chamber
as described in Sovány et al. (2009) and conducted examinations
to reveal the possible interactions between the drug and the excip-
ients. We offer and examine the hypothesis that even if no chem-
ical interaction occurs between the drug layer and the coating, in
the case of water-soluble drugs changes in crystallinity can be ex-
pected due to migration.2. Materials
Diltiazem hydrochloride (Ph. Eur., a gift from EGIS Ltd., Buda-
pest, Hungary) was used as a model drug, Cellet 500 (Shin-Etsu
Chemical Co., Ltd., Tokyo, Japan, granted as a gift from Harke Phar-
ma) as nonpareil core material, Kollidon 25 (donated by BASF, Lud-
wigshafen, Germany) and Pharmacoat 606 (BASF, Ludwigshafen,
Germany) was applied as a binder in the layering of diltiazem
hydrochloride, and Acryl-EZE (kindly granted by Colorcon, Dartford
Kent, UK), a fully formulated enteric coating dispersion, was used
as coating material.3. Methods
3.1. Preparation of samples – layering of diltiazem hydrochloride
The multiparticulate pellet samples were prepared in a Strea-1
(Niro Aeromatic, Bubendorf, Switzerland) ﬂuid bed chamber.
564 K. Nikowitz et al. / European Journal of Pharmaceutical Sciences 48 (2013) 563–571In the ﬁrst, drug-loading step, diltiazem hydrochloride was lay-
ered onto nonpareil Cellet 500 cores. A solution of diltiazem hydro-
chloride and Kollidon 25 or Pharmacoat 606 in a mass ratio of 5:3
and 5:2 respectively was used, as the solution containing only dil-
tiazem hydrochloride did not yield satisfactory loading results on
previous occasions. A batch size of 200 g of nonpareils and the
above-mentioned solution containing 125 g of API was used. The
loading parameters were: inlet temperature 50 C, outlet tempera-
ture 43 C, fan capacity 4.5, peristaltic pump speed 4 ml/min, air
volume 75 m3/h, blow-out pressure 4.4 bar, atomizing pressure
2 bar and nozzle diameter 1 mm.
Between the drug-loading and the following coating the pellets
were dried in the spray coater for 10 min. Since the Acryl-EZE con-
tains sodium bicarbonate as an excipient, the equipment had to be
completely disassembled and washed to prevent precipitate
formation.
At this point samples of the drug-loaded nonpareils were taken
for comparison purposes; these are called Samples 1a and 1b from
here on.3.2. Preparation of samples – coating
In the second, coating step, a 20% aqueous dispersion of
Acryl-EZE (a fully formulated USP copolymer type C coating system
containing 60% polymer and various excipients) was prepared and
applied as per the guidelines of the manufacturer. 0.1% of dimeti-
cone was added to prevent foaming during the stirring and coating
process. The parameters of the coating were the same as for the
drug layering step. Calculated from the amount of coating disper-
sion, the amount of dry material consumed for 200 g of drug-
loaded particles was 60 g and 120 g with an about 8% loss in all
cases. The coated pellets will be called Samples 2 and 3 in order
of increasing ﬁlm thickness from here on (Table 1).
Samples were prepared later to outrule interactions. These are
labeled Samples A–C and were prepared with the methods de-
scribed above with one or more of the materials left out as indi-
cated in Table 1.3.3. Differential scanning calorimetry
Differential Scanning Calorimetry (DSC) was performed with a
Mettler–Toledo DSC 821e (Mettler–Toledo GmbH, Switzerland)
instrument. DSC curves were evaluated with STARe Software. The
starting and ﬁnal temperatures were 0 C and 400 C and heating
rate was 10 C/min. Argon atmosphere was used in all cases. Three
parallel examinations were done from all samples. The instrument
was calibrated using indium. Samples were measured in a 40 ll
aluminium pan.Table 1
Samples produced.
Sample API
(125.0 g)
Kollidon 25
(75.0 g)
Pharmacoat 606
(50.0 g)
Acryl-EZE
(g)
1a U U – –
2a U U – 60
3a U U – 120
1b U – U –
2b U – U 60
3b U – U 120
A U – – 75
B – U – 120
C – – – 120
API and/or Kollidon 25 or Pharmacoat 606 layered from aqueous solution at 50 C.
Acryl-EZE coated from 20% aqueous dispersion at 50 C.3.4. Thermogravimetric analysis
Thermogravimetric Analysis (TGA) was carried out with a
Mettler–Toledo TGA/DSC1 (Mettler–Toledo GmbH, Switzerland)
instrument. Curves were evaluated with STARe Software. The start-
ing and ﬁnal temperatures were 0 C and 400 C and heating rate
was 10 C/min. Sample weight varied between 10 and 12 mg.
3.5. Powder X-ray diffractometry (XRPD)
The X-ray powder diffraction patterns (XRPDs) were obtained
with a Brucker D8 Advance (Brucker AXS, Germany) equipped with
a Sycos H-Hot (Ansyco GmbH, Karlsruhe, Germany) programmable
plate holder. Results were detected with a Våntec-1 detector. The
patterns were recorded at a tube voltage of 40 kV, tube current
of 40 mA, applying a step size of 0.01 Å 2h in the angular range
of 3–40 Å 2h.
3.6. Hot-stage microscopy
Thermomicroscopic investigations were carried out with a Ni-
kon Michrophot FXA polarizing microscope (Nikon Corporation,
Tokio, Japan) ﬁtted with a Linkam THMSG-600 heating-freezing
stage (Linkam Scientiﬁc Instruments, Waterﬁeld, UK). Photographs
were taken with a digital camera (UBS 2 UI-1640LE-C, IDS Imaging
Development Systems GmbH, Obersulm, Germany). Pellets were
carefully crushed and intact coating ﬂakes chosen from the grist.
3.7. Fourier-transformed infrared spectroscopy
FT-IR measurements were performed by an Avatar 330 FT-IR
spectrometer (Thermo Nicolet/Thermo Fisher Scientiﬁc Inc.,
Ramsay, Minnesota, USA) equipped with a horizontal ATR crystal
(ZnSe, 45). Spectra were recorded between 4000 and 400 cm1
at 4 cm1 optical resolution. Spectra were collected in absorbance
mode using the KBr disk method (0.5 mg powdered sample in
150 mg KBr disk). 256 scans were co-added. Spectra were collected
with the EZ Omnic software and analyzed with GRAMS AI.
3.8. Dissolution studies
Dissolution studies were carried out according to the Ph. Eur.
standards with a rotating basket (Erweka DT 700, Erweka GmbH,
Heusenstramm, Germany), in 1000 ml of simulated gastric acid
at 100 rpm at 37 C for 2 h, then the acidic medium was replaced
with 1000 ml of phosphate buffer (pH = 6.8) and the dissolution
measured at the same parameters as above. Samples were taken
of the gastric acid at 2 h and of the phosphate buffer at 5, 10, 15,
20, 30, 45, 60 and 90 min.
Concentration was measured with a spectrophotometer (Uni-
cam Helios a, Thermo Fisher Scientiﬁc Inc., Waltham, USA) at
237 nm, with a bandwidth of 2 nm and a lamp charge of 325 nm
by comparison to a calibration curve.
The drug content of the pulverised pellets was determined in
phosphate buffer after 2 h at the same parameters as for the disso-
lution test. Results were analyzed with Microsoft Excel 2007.
4. Results
4.1. Differential scanning calorimetry
The DSC curves of the materials are presented in Fig. 1. The
results are consistent with literary data (Zhang et al., 2008;
Reverchon et al., 2008; Hekmatara et al., 2006). The endothermic
peak signaling the melting of diltiazem HCl can be seen at
K. Nikowitz et al. / European Journal of Pharmaceutical Sciences 48 (2013) 563–571 565214 C; the second, broad endothermic peak on the curve can be
attributed to API degradation. Kollidon 25 and Pharmacoat 606
both exhibit a broad endothermic peak that indicates water loss.
No glass transition temperature could be determined for the poly-
mers (Zidan et al., 2012). The Tg of Acryl-EZE is clearly visible, but
no other characteristic peaks appear on the curve.
As shown in Fig. 2, an exothermic peak appeared at about
100 C on the DSC curves of the coated pellets. The Tg of Acryl-
EZE did not shift signiﬁcantly and no other Tg or peak was observed
on the curves before the API melting point. The exothermic peaks
were always followed by the endothermic peak characterizing
the melting of diltiazem HCl.
An amorphous sample of diltiazem HCl was prepared by melt-
ing and rapid cooling to measure the Tg. The DSC curve in Fig. 3Fig. 1. DSC curves of t
Fig. 2. DSC curves of Sampexhibits this at 100 C. Also in Fig. 3 is the curve obtained from a
repeated heating of Sample 3a. The exothermic peak appears only
during the ﬁrst heating cycle.
Fig. 4 shows that a similar peak appeared at about 180 C or
directly before the melting point on the curves of the uncoated
API-layered pellets depending on the binder used in the
sample. No other composition results in exothermic peaks in the
curve.
4.2. Thermogravimetric analysis
Fig. 5 shows that no signiﬁcant weight loss occurs in the ther-
mal range of the exothermic peaks. Signiﬁcant weight loss starts
approximately at the melting point of diltiazem HCl.he base materials.
les 2a–3a and 2b–3b.
Fig. 3. Thermal behavior of amorphous API.
Fig. 4. Thermal analysis of the exothermic peak.
566 K. Nikowitz et al. / European Journal of Pharmaceutical Sciences 48 (2013) 563–5714.3. Powder X-ray diffractometry (XRPD)
As shown in Fig. 6 the XRPD spectrum of diltiazem HCl contains
several peaks of different sizes; the larger ones can be detected in
the spectrum of Sample 1 at 4.125, 8.328, 9.907, 10.547,
18.070, 19.442, 21.661 and 27.575 2h. Cellet 500, Kollidon 25
and Pharmacoat 606 do not produce sharp peaks but appear as
broad backgrounds which do not hinder the identiﬁcation of the
sharp peaks from other materials. Acryl-EZE has two sharp peaks
in the spectrum; these were identiﬁed as talc, listed as an ingredi-
ent by the manufacturer.
The XRPD spectra were detected at room temperature at base-
line and heated to 120 C and 200 C as they are slightly above
the range of the exothermic peaks observed in Figs. 2 and 4. Theresults are presented in Figs. 7 and 8. The spectrum of the coated
samples contains a sharp peak at 25.648 2h, which was identiﬁed
as titanium dioxide (Parker, 1924), an ingredient of the Acryl-EZE
coating system. All coated and the Kollidon-containing uncoated
samples contain crystalline API at baseline. In all cases diltiazem
peaks have become larger (in some cases, appear) after the heat
treatment. Also, in the case of the coated samples almost all of
the diltiazem peaks are visible in the spectrum of the heat-treated
sample, whereas only the peaks at 9.907, 10.547, 15.897,
18.070, 19.442 and 21.661 2h were prominently present before.
In the case of the uncoated samples API peaks only appeared/grew
after the 200 C heat treatment. Comparing 120 C and 200 C heat
treated (coated) sample spectra, a decrease in API peak heights can
be observed.
Fig. 5. DSC and TG curves of Samples 1a and 2a.
Fig. 6. X-ray spectra of the materials.
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Fig. 9, the polarized light microphotograph of a piece of coating
taken using crossed Nicols shows that the polymeric ﬁlm layercontains some dispersed crystalline material even before the
heat treatment (left side). After the heat treatment (right side)
the amount of birefringent particles in the coating increased
signiﬁcantly.
Fig. 7. X-ray spectra of the coated samples before and after heat treatment.
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The FT-IR spectra of a coated sample before and after heat treat-
ment in the DSC equipment is shown in Fig. 10. Both the samples
and the physical mixture of binder and API contain a water peak
at 3450 cm1, although the heat treatment appears to have signif-
icantly reduced the water content of the sample. Compared to the
spectrum of the physical mixture several peaks in the un-treated
sample are less prominent (if there at all) and wider, less sharp. De-
spite this no shifts in peak positions can be observed indicating
that no chemical bonds were formed between API and polymers.
The spectrum of the heat treated sample appears to be fundamentally
the same as the physical mixture spectrum with slight differences
that can be attributed to the presence of other excipients. FT-IR
spectra of Sample set b have yielded similar results.4.6. Dissolution studies
The dissolution of the coated samples before and after heat
treatment in the DSC equipment is shown in Fig. 11. While the gas-
troresistance of Samples 2a and 3b improved signiﬁcantly the
change observed in the case of Sample 3a is well beneath the SD
value. Sample 2b’s coating level proved to be insufﬁcient for
signiﬁcant gastroresistance and thus its dissolution tests were
discontinued.5. Discussion
In Fig. 2 an exothermic peak appeared at about 100 C on the
DSC curves of the coated pellets. The peak only occurred in samples
containing both diltiazem hydrochloride and the Acryl-EZE coating
(see Fig. 4), suggesting that it is a result of an interaction between
these two materials. According to the manual Acryl-EZE containssodium bicarbonate, which, unlike the polymers used in the study,
has a known interaction with diltiazem hydrochloride (Pillay and
Fassihi, 1999): in aqueous media the diltiazem base precipitates.
The melting point of diltiazem base is in the same thermal range
as the exothermic peak, however, no signs of melting appear on
the curves and even though the interaction is known to exist, an
undetectable amount of sodium bicarbonate is not likely to pro-
duce detectable amounts of diltiazem base in the ﬁrst place.
The nature of the preparation procedure indicates that a solid
dispersion can be formed during API layering that, depending on
the composition and parameters, can contain the API in amorphous
and/or crystalline form (Zhang et al., 2008). The X-ray analysis con-
ﬁrmed that the transformation causing the exothermic peak at
100 C is caused by the recrystallization of the API. In the un-
coated samples the amorphous API only recrystallizes upon or
close to melting (see Figs. 4 and 8).
Fig. 9 shows that the API migrated into the coating layer and re-
mained in amorphous clusters that later crystallize if subjected to
heat treatment. The probable explanation for this is that diltiazem
HCl as a highly water-soluble drug dissolved into the droplets of
the coating suspension during the coating. The plasticization
mechanism described by Mizuno et al. can also play a role in the
process (Mizuno et al., 2005). Binder polymers might also play a
part in the phenomenon by forming solid dispersions with the
API upon layering, from which the amorphous API dissolves more
readily than from a fully crystalline API layer (Konno et al., 2008;
Van den Mooter et al., 2001; Sun et al., 2008; Zhang et al., 2008).
This hypothesis is supported in Fig. 3, as no exothermic peak ap-
pears on the DSC curves of the sample prepared without a binder.
The migration from the drug layer to the coating probably occurs
mostly before a thin uniform coating layer forms on the drug-
loaded cores (Mizuno et al., 2005).
Considering the fact that the migration thus affects only a small
fraction of the API and the drug layer already contains an
Fig. 8. X-ray spectra of the uncoated samples before and after heat treatment.
Fig. 9. Polarized light microphotograph of the coating before and after heat treatment.
K. Nikowitz et al. / European Journal of Pharmaceutical Sciences 48 (2013) 563–571 569amorphous fraction, migration does not explain the different
recrystallization behavior of the coated and uncoated samples. AsFTIR spectra show no evidence of chemical bonds between poly-
mer and the API in either case only physical inhibition prevents
Fig. 10. FT-IR spectrum of Sample 2a after heat treatment, Sample 2a and physical
mixture of diltiazem HCl + Kollidon 25 (from top to bottom).
570 K. Nikowitz et al. / European Journal of Pharmaceutical Sciences 48 (2013) 563–571the drug from completely crystallizing during sample preparation
and storage (Van den Mooter et al., 2001). In such cases the main
reason for recrystallization is the glassy to rubbery state transition
of the polymer and the increased molecular mobility of the API
(Konno et al., 2008; Van den Mooter et al., 2001). It is known that
the physical stability of a drug depends greatly on the preparation
method and the polymer carrier (Crowley and Zograﬁ, 2002; Van
Eerdenbrugh and Taylor, 2010; Bley et al., 2010). In our case the
methods of preparation were the same for all samples but the
amorphous API is located partly in the coating layer and partly in
the drug layer, which means that if no other underlying mecha-
nism exists, we should observe two phases in the recrystallization:
one for the drug layer and one for the coating (or only one if they
overlap). However only one was observed and at signiﬁcantly low-
er temperatures than in the uncoated samples.
According to our results this phenomenon must be explained by
the presence of the coating. The DSC curves of the uncoatedFig. 11. Dissolution of coated samplessamples in Fig. 5 show a broad endothermic peak that literature
attributes to the loss of water in PVP and HPMC, respectively. This
peak is not present in the coated samples indicating a quasi-water-
tight property of the coating on the timescale of the DSC analysis.
The exothermic peak attributed to API recrystallization coincides
with the boiling point of water which raises the question: does
water play a role in the recrystallization (Wu et al., 2012)?
Several well-described phenomena can be used to explain the
possible inﬂuence of water on the recrystallization behavior of
our coated samples (Baird and Taylor, 2012; Malaj et al., 2010).
Many studies proved that water acts as a plasticizer in polymer
drug delivery systems; as a plasticizer it can decrease the Tg of
the polymer to the observed range – which it cannot do for the un-
coated samples as the unhindered evaporation reduces its amount
by the time the sample reaches the temperature range in question
(Pirayavaraporn et al., 2012). Water can also be contained in the
microcrystalline cellulose core. As a highly water-soluble drug, dil-
tiazem hydrochloride can dissolve in the water migrating toward
the surface of the pellet from the core and crystallize from the solu-
tion. As water boils in the thermal range of the recrystallization
peak, the pressure of steam in the pores of the pellet is expected
to grow rapidly at the time. Since water also acts as a plasticizer,
pores can be expanded essentially removing the physical barrier
that stood in the way of recrystallization. The process is well-
known and routinely used in the food industry but a similar effect
achieved during the use of supercritical or pressurized carbon
dioxide in the pharmaceutical industry has been described (Var-
nalis et al., 2001; Norton et al., 2011; Verreck et al., 2005, 2006,
2007).
These mechanisms can and probably do work independently at
the same time. To determine the most important among them and
explore its implications regarding the stability of the system, many
difﬁculties will have to be overcome. A method should be devised
to measure the position of water and pore size inside the pellet
without removing the coating. Studies on stability should take into
consideration that the generally used high relative humidity will
probably cause an unrelated recrystallization phenomenon by
plasticizing the polymer that would not happen at ambient condi-
tions (Malaj et al., 2010).
Similar problems arise when trying to determine the signiﬁ-
cance of recrystallization on the dissolution behavior of the pellets.before and after heat treatment.
K. Nikowitz et al. / European Journal of Pharmaceutical Sciences 48 (2013) 563–571 571As recrystallization involves heat treatment, it is logical to assume
that a curing of the coating also takes place which (while further
limiting water evaporation from the sample) would affect the out-
come of a later dissolution test (Pirayavaraporn et al., 2012; Musc-
hert et al., 2009). Also if the expansion of the pores described above
is signiﬁcant enough to expand the pellet, the coating polymer
would either rupture or, which is more probable given that it
transforms into the rubbery state at the temperature involved,
would stretch and transform back into the glassy state upon cool-
ing. Both of these mechanisms would result in worsening gastrore-
sistance, unlike the curing effect which has been described to
improve results signiﬁcantly (Muschert et al., 2009; Gendre et al.,
2012). The extent of the API migration and the ﬁlm thickness
would probably also inﬂuence the results. The preliminary dissolu-
tion tests presented in this article suggest that no rupturing
occurred in the samples and in some cases the sum of the effects
described above could signiﬁcantly improve gastroresistance.6. Conclusion
DSC analysis of the coated pellets showed an exothermic peak
that is not characteristic of any of the materials used. Further
examination revealed that this is due to the recrystallization of
amorphous diltiazem HCl present in the ﬁlm coating. This conﬁrms
our hypothesis that water-soluble drugs are subject to signiﬁcant
migration when coated with aqueous systems and thus the poly-
mers used for coating must be taken into account when determin-
ing the crystallinity of the API.
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Bevezetés
A módosított hatóanyag-leadású készítmények térnye-
résével számtalan új gyógyszerforma alakult és alakul 
ki. A jelenség nagy győztesei az úgynevezett multi-
partikuláris rendszerek, amelyek (a hagyományos 
gyógyszerformákkal szemben) sok kisebb, egyedi hor-
dozóegységben tartalmazzák a hatóanyagot. Legelter-
jedtebb formájuk a kapszulába töltött pelletek, de tab-
lettává préselve is forgalomba kerülnek [1].
A pelletek többnyire egyenletes felületű, ennek kö-
vetkeztében jó folyási tulajdonságokkal rendelkező, 
tömött szerkezetű, közel gömb alakú granulátumok. A 
hagyományos gyógyszerformákkal szemben előnyük 
a sokoldalú alkalmazhatóság, a megnövekedett ab-
szorpció és a csökkent irritáció, a nem kívánt ható-
anyag-felszabadulás kockázatának csökkenése, vala-
mint az inkompatibilitások elkerülése [1-11].
A pelletek előállításának lehetséges módja a felépí-
téses technológia (pl. rotofl uid granulálás), valamint 
az extrudálás-szferonizálás. Mindkét esetben lehetsé-
ges további rétegek felvitele a pelletre az ún. réteg zé-
ses eljárással [11-13].
A rétegzéses eljárás során a ható- és segédanyago-
kat rétegekben visszük fel egy korábban elkészített 
magra. A mag lehet inert (ezek általában cukrok, cu-
korszármazékok, vagy készülhet cellulózból stb.), il-
letve tartalmazhat hatóanyagot is. A felvitt rétegek 
számában és funkciójában is lehet különbség. Az 1. 
ábrán egy indifferens maggal készült rétegzett pellet 
szerkezete látható. A rétegek száma és vastagsága meg 
kell feleljen a hatóanyag anyagi sajátságainak, terápiás 
adagjának, ill. az adott alkalmazási célnak.
Működési elvek és berendezések
A rétegzéses eljáráshoz többféle berendezés használ-
ható. Kezdetben a cukros drazsírozásra használt üstöt 
alkalmazták, azonban ez több szempontból nem volt 
ideális megoldás. A porlasztáshoz és a szárításhoz 
használt levegő eltávozása csak az üst száján keresztül 
lehetséges, ahová szűrő nem építhető be, így a kis tö-
megű apró szemcsék eltávozása komoly gondot, a visz-
szatartása pedig komoly feladatot jelent. Ezenkívül a 
rétegzett anyag egyenletes eloszlása az üst alakjától és 
dőlésszögétől függ, így a holtterek keletkezésével is 
számolni kell.
Az előbb felvázolt problémák kiküszöbölése céljá-
ból, ill. a nagyobb hatékonyság érdekében hamar át-
tértek a centrifugál-granulátorok, ill. a rotofl uid 
granulátorok alkalmazására. Az ilyen típusú berende-
zésekben közös, hogy ideális esetben a magok nedve-
sedése és száradása folyamatosan egyensúlyban van 
és igen rövid idő alatt végbemegy, így a hatóanyag 
Rétegzéses technológia elve és alkalmazási lehetősége 
multipartikuláris rendszerekben
Nikowitz Krisztina, Hódi Klára, ifj. Regdon Géza
1. ábra: Multilayer pellet sematikus ábrája 2. ábra: A centrifugál-granulátor működése [2]
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száradása a magok felületén gyorsan megtörténik, ez-
zel csökkentve az anyagveszteséget. A gyors száradás 
és az ebből következő kis nedvességtartalom miatt a 
magoknak nincs alkalma összetapadni [2].
A centrifugál-granulátorokban a szemcsék összetett 
mozgást végeznek (lásd 2. ábra): a tányér szélén fölfe-
lé haladó levegőáram hatására a magok megemelked-
nek, a tányér közepe felé esnek, majd leérkezve a cent-
rifugális erő ismét a tányér széle felé taszítja őket, így 
folyamatosan mozgásban vannak. A tányér forgása 
eközben szintén hat a szemcsékre, így azok önmagába 
visszatérő, spirál alakú utat járnak be [2, 14, 15].
A fent vázolt berendezés egyik legfontosabb jellem-
zője, hogy „nyitott” üzemi technológiájú, míg a ha-
sonló elven működő, de „zárt” elvű készülékek az ún. 
„Rotofl uid” berendezések; a gyógyszeripar elsősorban 
ezeket használja.
Az Innojet új berendezésében (lásd 3. ábra) már a 
tányér forgatása helyett a tányért alkotó koncentrikus 
fémlemezek közötti réseken irányítottan kiáramló le-
vegő kényszeríti az anyagot a berendezés széle felé. 
Az eljárás előnye az egyenletes levegőáramlás és a 
sokoldalú felhasználhatóság. Ipari szempontból a be-
rendezés könnyű szerelése és tisztítása, valamint a fel-
építéséből következő lineáris léptéknövelhetősége 
emelhető ki.
A leggyakrabban használt berendezés fl uidizációs 
elven működik, amelyben az alulról jövő levegőáram 
emeli fel a magokat a kolonnában, majd azok a sebes-
ségcsökkenés miatt visszahullanak a berendezés aljá-
ra. Ennek bevonásra és rétegzésre optimalizált válto-
zata a Wurster módszer (lásd 4. ábra). A berendezés-
ben térelválasztóként egy csövet helyeznek el. A ma-
gok felfelé történő mozgása irányítottan a cső belsejé-
ben, lefelé esése a cső körül történik. A lehullott 
magokat a nagy sebességgel áramló levegő szívó hatá-
sa visszahúzza a cső alá, így a magok folyamatosan 
mozgásban maradnak [2, 16].
A fl uidizációs berendezésnek több módosított válto-
zata született. A pulzáló fl uidágyas berendezésben a 
levegő áramlása a perforált lemeznek egyszerre csak 
egy részére koncentrál, és időben váltakozva mozgatja 
át a teljes magágyat [17]. 
Rétegzéses hatóanyag-felvitel
A különböző rétegek felvitele az anyagok tulajdonsá-
gaitól függően többféleképp történhet. Vízben jól ol-
dódó hatóanyagok esetében az oldatos, rosszul oldódó 
anyagok esetében a szuszpenziós felvitel, vagy a 
porrétegzés alkalmazható. A szerves oldószerek hasz-
nálata környezetvédelmi és költséghatékonysági okok-
ból, valamint az oldószermaradványok jelentette prob-
lémák miatt kiszorulóban van [2, 18].
Oldatok és szuszpenziók rétegzésénél a hatóanyagot 
minél magasabb koncentrációban érdemes felvinni, 
mert az oldószer eltávolításának sebessége határozza 
meg a művelet idejét, energiaigényét és a részecskenö-
3. ábra: Az Innojet Ventilus készülék működése
Jelmagyarázat: 1 – külső fal; 2 – alsó tányér levegőnyílá-
sokkal; 3 – Rotojet porlasztó; 4 – Sepajet porvisszavezető 
rendszer; 5 – szűrőtartó elem; 6 – szűrőtisztító levegő; 
7 – szűrők feletti rotor; 8 – szűrők feletti rotor meghajtása; 
9 – lebegtető levegő bevezetése; 10 – levegő kivezetése; 
11 – centrálisan bevezetett levegő
4. ábra: A fl uidizációs bevonó és részei
Jelmagyarázat: A – műveleti tér fala; B – térelválasztó 
kolonna; C – perforált lemez; D – porlasztó; E – expanziós 
kamra [2]
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vekedés sebességét. Szuszpenziók esetében célszerű 
minél kisebb szemcseméretben alkalmazni a ható-
anyagot, mivel a kialakuló felület egyenletessége a 
szemcsemérettel fordítottan arányos, valamint a na-
gyobb részecskék hajlamosabbak letöredezni a ma-
gokról [2, 19]. 
Porok rétegzése esetén a hatóanyagot szilárd for-
mában adagolják a berendezésben lévő magok felüle-
tére, miközben a kötőanyagot tartalmazó folyadékot 
porlasztva juttatják a rendszerbe. A por kis szemcse-
mérete miatt általában glidánsok alkalmazására is 
szükség van [20-21].
A műveletben használt porlasztó általában a beren-
dezés alján helyezkedik el, és a levegőáramlással azo-
nos irányba (függőlegesen felfelé) porlaszt. Laborató-
riumi méretű berendezésekben általában egy porlasztó 
üzemel a berendezés közepén, míg nagyobb gépek, 
üzemi berendezések esetében a porlasztók egyenlő tá-
volságra, koncentrikus körökben találhatók. Utóbbi 
megoldás hátránya, hogy a porlasztók egyikénél fellé-
pett probléma a termék teljes mennyiségére van hatás-
sal, így a potenciális veszteség nagyobb. 
A készülékeknél említett Innojet berendezésben a 
fúvókának nem a csúcsán, hanem a peremén találha-
tók a folyadékot és a porlasztó levegőt adagoló rések 
(lásd 5. ábra). A vízszintes porlasztó két ellentétes irá-
nyú nyalábban porlaszt, a termék egyenletes nedvesí-
tését a porlasztófej forgása biztosítja.
A magok folyamatos mozgása miatt a felszínükön 
képződő réteg folyamatos eróziónak van kitéve, amely 
részben az ütközésekből, részben a levegő áramlásából 
ered. Minél gyorsabb a magok mozgása, annál erő-
sebb és több ütközés zajlik a magok, illetve a magok 
és a berendezés falai között, és minél nagyobb a leve-
gőáram, annál gyorsabban, akár még a magok elérése 
előtt távozik a hatóanyag a rendszerből, illetve annál 
nagyobb eséllyel sodorja le a gyengén kötött hatóanya-
got a mag felszínéről [2]. Ezért fontos a levegőáram és 
a többi paraméter megfelelő szinkronizálása.
A kitermelés növelése érdekében szinte minden 
esetben alkalmaznak kötőanyagokat. Ezek általában 
alacsony molekulatömegű polimerek, amelyeket a fo-
lyékony fázisban oldva visznek be a rendszerbe. Kez-
detben a folyadék alkotta hidak, majd a száradás után 
a feloldódott hatóanyagból vagy a polimer kötőanyag-
ból képződött szilárd hidak tartják a helyén a ható-
anyagréteget [2].
Egy magra több különböző hatóanyag is rétegezhető, 
az inkompatibilitások fi gyelembe vételével akár egy-
szerre, akár egymást követően. Több pumpa megfelelő 
programozásával akár egy rétegen belül is fokozatosan 
változó összetételt érhetünk el. Egymással inkompatibi-
lis hatóanyag- illetve bevonatrétegek közé elválasztó ré-
teget iktatnak, ami megakadályozza a kritikus kompo-
nenseket tartalmazó rétegek érintkezését [22].
Bevonatként – amennyiben szükséges – a tabletták 
bevonásánál megszokott anyagok jöhetnek szóba. 
Megfelelő polimerek, ill. több különböző bevonatréteg 
alkalmazásával módosított hatóanyag-leadó (nyújtott, 
késleltetett, pulzáló stb.) rendszerek hozhatók létre.
Kritikus paraméterek
Minden eljárásnál különös fi gyelmet kell fordítani a 
kritikus paraméterek meghatározására, művelet köz-
beni folyamatos ellenőrzésükre. A kritikus paraméte-
rek köre nemcsak az anyagi rendszerek összetételétől 
függ, hanem az egyes technológiák, előállítási elvek 
esetében is jelentős eltéréseket mutathat, ezért megha-
tározásuk különösen fontos [23].
A hagyományos drazsírozó üstnél az üst alakja, a 
forgástengely dőlésszöge, a terelőlapátok állása és a 
forgási sebesség, míg a centrifugál-granulátor és a 
fl uidizációs berendezés esetében a porlasztó levegő 
nyomása, a szárító levegő hőmérséklete, a levegő ned-
vességtartalma, a por ill. a folyadék adagolási sebessé-
ge, a fúvóka átmérője számítanak elsősorban kritikus 
paraméternek. A centrifugál- ill. rotofl uid granulá-
torokban a rétegzett anyag egyenletes eloszlatását el-
sősorban a tányér megfelelő forgási sebességével lehet 
biztosítani, de fontos paraméter a szárító levegő térfo-
gata és sebessége, a fúvóka átmérője, valamint a 
sarzsméret is. A szárító levegő sebessége bizonyos be-
rendezéseken a tányér és a berendezés fala közötti rés 
nagyságának változtatásával szabályozható [24].
5. ábra: Rotojet porlasztó működési elve
Jelmagyarázat: 1 – folyadékréteg; 2 – alsó porlasztó 
levegő; 3 – felső porlasztó levegő; 4 – felső védő 
levegőréteg, 5 – védőkúp; 6 – meghajtó tengely; 
7 – külső védőburkolat; 8 – tömítés
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A fl uidizációs berendezésekhez általában több kü-
lönböző lyukméretű perforált lemez tartozik, így a 
szárító levegő mennyisége bizonyos keretek között 
változtatható. Természetesen mód van az áramlási se-
besség szabályozására is. Kritikus paraméter továbbá 
a szuszpenzióban történő hatóanyag-felvitel esetén a 
hatóanyag szemcsemérete is [2, 25].
A rétegzéses eljárás a komoly felszereltség mellett 
is nagy szakértelmet kíván, hiszen a termék minősé-
gét rengeteg paraméter befolyásolja. A kritikus para-
méterek folyamatos ellenőrzése ezért kiemelten fon-
tos [23].
A rétegzéses eljárás számos jelentős gyógyszer-
technológiai probléma megoldására alkalmazható. Se-
gítségével egyszerűen állíthatók elő a hatóanyag 
amorf formáját tartalmazó szilárd oldatok, mivel a kö-
tőanyagként használt polimerek egy része kristályoso-
dást gátló tulajdonságokkal is rendelkezik [26-27]. 
Sokoldalúan módosítható a termék hatóanyag-leadása 
mind a segédanyagok, mind az egyes rétegek megfele-
lő megválasztásával. Egy készítményben feldolgozha-
tóvá válik számos, akár egymással inkompatibilis ha-
tóanyag is, és az egyes hatóanyagok leadása időben és 
egymáshoz viszonyítva pontosan szabályozható. A 
rétegzéses eljárással előállított pelletek később több 
gyógyszerformában is feldolgozhatók.
Gyógyászati alkalmazásuk
Magyarországon jelenleg elsősorban nyújtott ható-
anyag-leadású ill. savrezisztens készítmények kerül-
nek így forgalomba. A rétegzéses eljárás ezenkívül 
különösen alkalmas pulzáló hatóanyag-le-
adás elérésére: a pelletek legkülső bevo-
natrétege oldhatatlanságával vagy savre-
zisz tens mivoltával biztosítja a kezdeti 
késleltetett kioldódást az alatta levő ható-
anyagrétegből, majd a hatóanyagréteg fel-
oldódása után az ez alatt található bevo-
natréteg késleltető hatása érvényesül, majd 
kioldódik az alatta levő hatóanyagréteg, és 
így tovább, egészen az inert magra közvet-
lenül felvitt hatóanyagrétegig.
Ezek gyakorlati megvalósításához általá-
ban rupturáló bevonatokat, illetve eseten-
ként az azokra rétegzett oldhatatlan, de per-
meábilis fi lmeket használnak. Az FDA által 
Pulsys néven engedélyezett ilyen típusú ké-
szítmény amoxicillint tartalmaz [3, 23].
Ígéretes kísérletek történtek rétegzéses 
eljárással készített úszó rendszerek előállí-
tására [28-29]. Bizonyos oldhatatlan per-
meábilis polimerek alkalmasak arra, hogy 
az alattuk elhelyezkedő efferveszcens ré-
tegben termelődő gázt csapdába ejtve akár 
24 órán keresztül is lebegésben tartsák a 
pelleteket. A polimer a kioldódást a megszokott mó-
don befolyásolja.
A rétegzett pelletek – mint a pelletek általában – 
kapszulába tölthetők vagy tablettává préselhetők. A 
rétegzett pelletekből préselt tabletták előállítása sok 
kihívással jár. A multipartikuláris rendszerek előnyei-
nek megtartása érdekében az egyes pelletek a préselés 
során nem veszíthetik el egyediségüket, illetve a meg-
felelő hatóanyag-kioldódást biztosító bevonataik nem 
sérülhetnek. A kész termék ugyanakkor rendelkezik a 
tabletták kényelmes bevehetőségével, esetleges felez-
hetőségével, valamint gyors szétesésénél fogva nyelési 
nehézségeket sem okoz [30-31]. Az így előállított ké-
szítmények általában módosított hatóanyag-leadásúak, 
külföldön MUPS megjelöléssel kerülnek forgalomba. 
A tablettázás nehézségeinek elkerülésére a pelletek 
gyorsan széteső gélmátrixba inkorporálásával is kísér-
leteznek [32].
Összefoglalás
Összességében elmondható, hogy a rétegzéses eljárás 
számtalan, (Magyarországon) még kihasználatlan le-
hetőséget rejt magában, amelyek gyakorlati felhaszná-
lásához és a megfelelő betegtájékoztatáshoz elenged-
hetetlen a háttérben levő technológia ismerete. A 
rétegzéses eljárást ugyan nem egyedül a gyógyszer-
iparban alkalmazzák, de működése minden iparágban 
azonos műszaki elven zajlik, így alapvetően azonos 
problémákat vet fel. Természetesen a gyógyszeripari 
alkalmazás az a terület, ahol a benne rejlő lehetősége-
ket a legjobban lehet kihasználni.
6. ábra: Rétegzéssel kialakított pulzáló rendszer sematikus ábrája [23]
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The highly water-soluble model drug diltiazem hydrochloride is a
ﬁrst-line antihypertensive and antianginal agent. In the treatment of
hypertension a once-daily dosage is preferred in consequence of
compliance issues. The extended-release diltiazem capsules available
on the market typically consist of rapid-release, delayed-release and,
for some products, immediate-release particle fractions [1].
Multiparticulate drug delivery systems consist of multiple discrete
drug-containing units, typically thousands of spherical pellets that are
ﬁlled into one capsule. The individual pellets in a multiparticulate
system can sometimes be divided into fractions according to their
size, coating, release properties, drug content, etc., offering a wide
range of possibilities for drug development. Multiparticulate drug
delivery systems are increasingly gaining favor on the market, as their
multiple-unit nature furnishes several beneﬁts over the more
traditional single-unit dosage forms [2,3]. These include a lower
irritative effect due to the decreased local concentration, less
individual differences in plasma concentration than with tablets [4],
a reduced risk of dumping, improved bioavailability [4], a large scale
of products to be covered (in terms of both dosage forms and release
kinetics) and an easy-to-solve approach to interactions [5,6].
Disadvantages include the large number of variables, multiple-step
manufacturing, high production costs, greater excipient requirements
and the need for advanced technology and trained operating
personnel [7].Pellets can be produced by the direct pelletization of the drug and
the excipients (matrix pellets) and the use of nonpareil seeds with
one or multiple layers of drug (layered pellets) [8,9]. Both types of
products can be further coated; in our case this was done with an
acrylic-based ﬁlm-coating product. In the latter case, the quality and
thickness of the ﬁlm layer can be greatly inﬂuenced by the drug layer
underneath [10]. Besides the surface characteristics and distribution,
this also means that the chemical characteristics of the ﬁlm layer can
vary because of the drug. It has been documented that diltiazem is
associated with the hydrophobic sites of cationic polymer coatings
and is retained during dissolution [11].
A number of ready-to-use coating dispersions are available on the
market for the achievement of various release proﬁles. Their use
eliminates the need for the development and preparation of the
coating suspension and they have therefore gained acceptance in the
pharmaceutical industry [12].
In our experiments, we used the solution layering technique to
make the multilayered pellets described below. Solution layering is a
process during which the active pharmaceutical ingredient (API) and
the excipients (typically binders and coating materials) are either
dissolved or suspended and sprayed onto the continuously drying
cores. The method can be used to dose multiple, even incompatible
APIs together and the further processibility of the pellets is good,
thanks to the narrow size distribution, the good ﬂow behaviour and
the dense surface [6].
In our experiments, we evaluated the possibility of a multi-
particulate delayed-release diltiazem product. We also investigated
the use of fully formulated coating systems as a possible method of
reducing the manufacturing steps. Our future goal is to formulate a
sustained-release capsule in which the delayed-release product
156 K. Nikowitz et al. / Powder Technology 205 (2011) 155–159described below can be used as a fraction as the release directly on the
absorption site is expected to yield better results in extending the
release time of the formulation.
2. Materials
Diltiazem hydrochloride (Ph. Eur.) was used as a model drug,
Cellet 500 (Shin-Etsu Chemical Co., Ltd., Tokyo, Japan) as nonpareil
core material, Kollidon 25 (BASF, Ludwigshafen, Germany) was
applied as a binder in the layering of diltiazem hydrochloride, and
Acryl-EZE (Colorcon, Dartford Kent, UK), a fully formulated enteric
coating dispersion, was used as coating material.
3. Methods
3.1. Preparation of samples — layering of diltiazem hydrochloride
The multiparticulate pellet samples were prepared in a Strea-1
(Niro Aeromatic, Bubendorf, Switzerland) ﬂuid bedWurster chamber.
In the equipment cores were ﬂuidized by ﬁltered and heated air. The
cores' fast upward movement takes place inside a partition coloumn
and slower downward movement on its sides. Liquid is sprayed onto
the cores from below. Schematic ﬁgure (Fig. 1) taken from Chan et al.
[13].
In the ﬁrst, drug-loading step of the process, diltiazem hydrochlo-
ride was layered onto the nonpareil Cellet 500 cores. In accordance
with the results of our preliminary examinations, a solution of
diltiazem hydrochloride and Kollidon 25 in a mass ratio of 5:3 with a
total solid content of 40% was used, as the solution containing only
diltiazem hydrochloride did not yield satisfactory loading results. A
batch size of 200 g of nonpareils and the above-mentioned solution
containing 197 g of dry material was used. The loading parameters
were: inlet temperature 50 °C, outlet temperature 43 °C, fan capacity
4.5, peristaltic pump speed 4 ml/min, air volume 75 m³/h and nozzle
diameter 1 mm.
Between the drug-loading and the following coating step the
pellets were dried in the spray coater for 10 min. Since the Acryl-EZE
containes sodium bicarbonate as an excipient, the equipment had to
be completely disassembled and washed to prevent precipitate
formation.
At this point samples of the intermediate product were taken for
comparison purposes; these drug-containing uncoated pellets are
called Sample 1 from here on.Fig. 1. Schematic picture of the Strea 1 ﬂuid bed chamber.3.2. Preparation of samples — coating
In the second, coating step, an Acryl-EZE dispersion (a fully
formulated USP copolymer type C coating system containing 60%
polymer and various excipients) was prepared and applied, following
the guidelines provided by the manufacturer, as a 20% aqueous
dispersion. A small amount (0.1%) of dimeticone was added to prevent
foaming during the stirring and coating process. The parameters used
for the coating were the same as for the drug layering step.
Different amounts of coating dispersion were sprayed onto 200 g
of drug-layered pellets in the Strea equipment. Four batches were
prepared with different amounts of coating dispersion for each. The
amount of the dry material consumed for 200 g of drug-loaded
particles was 59.5 g, 79.5 g, 99.3 g and 125.0 g, respectively with an
about 8% loss. The drug-layered pellets were pre-heated at a reduced
atomizing pressure for 10 min, coated at a gradually increasing spray
rate and dried in the equipment for 10 min afterwards. The coated
pellets will be called samples 2 to 5 in order of increasing dry material
consumed for the ﬁlm coating from here on (Table 1).3.3. Measurement of layer thickness
An image analysis method (Leica Quantimet 500 MC, Leica
Cambride Ltd, Cambridge, UK) was used to determine the thickness
of the layers on the pellets. The mean thicknesses were calculated via
the mean diameters of the particles, determined by measuring 300
particles of each batch with a stereomicroscope (Zeiss, Oberkochen,
Germany). Film thickness was also examined with Raman spectros-
copy; the results of that work were published independently [14].3.4. Scanning electron microscopy
Photographs of every batch were taken with a scanning electron
microscope (SEM) (Hitachi 4700, Hitachi Ltd., Tokyo, Japan) and
possible coating problems were identiﬁed. A sputter coating appara-
tus (Polaron E5100, Polaron Equipment Ltd., Greenhill, UK) was used
to induce the electric conductivity on the surface of the samples. The
air pressure was 1.3–13 mPa.3.5. Dissolution of diltiazem hydrochloride from pellets
Dissolution studies were carried out according to the Ph. Eur.
standards with a rotating basket (Erweka DT 700, Erweka GmbH,
Heusenstramm, Germany), in 1000 ml of simulated gastric acid at
100 rpm at 37 °C for 2 h, then after draining the vessel of the acid it
was replaced with 1000 ml of phosphate buffer pH=6.8 and the
dissolution measured at the same parameters as above. Samples were
taken of the gastric acid at 2 h and of the phosphate buffer at 5, 10, 15,
20, 30, 45, 60 and 90 min.
Concentration was measured with a spectrophotometer (Unicam
Heliosα, Thermo Fisher Scientiﬁc Inc.,Waltham,USA) at 237 nm,with a
bandwidth of 2 nm and a lamp charge of 325 nm by comparison to a
calibration curve.Table 1
Samples produced.
Samples Coating dispersion (g) Dry material consumed (g)
Sample 1 none (only contains the drug on
the nonpareil core)
none
Sample 2 300 62.40
Sample 3 400 79.48
Sample 4 500 99.34
Sample 5 600 124.96
Table 2
Film thicknesses of samples.
Samples Coating dispersion (g) Film thickness (mean; μm)
Sample 1 none (only API) none
Sample 2 300 15.5
Sample 3 400 23.5
Sample 4 500 28.9
Sample 5 600 44.4
157K. Nikowitz et al. / Powder Technology 205 (2011) 155–159The drug content of the pulverised pellets in the phosphate buffer
was determined after 2 h at the same parameters as for the dissolution
test.
4. Results and discussion
4.1. Preparation of the samples
The fan capacity and the ﬂuid feed rate proved to be the most
important parameters in our studies. A too low fan capacity often
resulted in the particles sticking to the inner surface of the vertical
cylinder. Agglomeration of the particles was never completely over-
comebutwhendiscontinuous sprayingwasemployed the agglomerates
broke down into individual particles shortly after the spraying process
was paused [15]. This method has the disadvantage of an excessively
long coating timebut decreasing theﬂuid feed rate increased the coating
time evenmore and did not eliminate agglomeration completely. Use of
a higher ﬂuid feed rate resulted in one large agglomeration that blocked
the inside of the cylinder and the experiment had to be discontinued.
4.2. Measurement of layer thickness
As illustrated in Fig. 2, two diameters of each sampleweremeasured
(white and grey boxes) and the mean (dotted line) and median
(uninterrupted line) calculated. Both the mean and median lines show
that the particle size increased from that of the nonpareil core in each
sample. As themedian represents the value that separates the lowerhalf
of the sample from the upper half, the shift of the median toward one
end of the scale and its difference from the mean value means that the
samples exhibited an increasingly skewed distribution; this corre-
sponded with the observation that larger particles tended to recieve a
thicker coating than smaller ones [16], which is a known occurence and
is mainly due to the fact that between equal masses of particles the one
consisting of larger spheres has the smaller surface area. The increase in
size was mostly due to the addition of the drug layer, but Fig. 2 clearly
reveals the shift in the graph with the amount of coating dispersion
used. The mean thickness of the ﬁlm coating is presented in Table 2.
The roundness distribution of the particles, where roundness was
calculated as the quotient of two diameters, (Fig. 3) did not change
signiﬁcantly during the process, suggesting that no serious coating
problems occurred.
4.3. Scanning electron microscopy
The characteristics of the drug-loaded pellets are clearly depicted
in Fig. 4. It can be observed that the API forms a relatively uniformFig. 2. Size distribution (breadth and length) of coated particles.drug layer on the core, though recrystallization causes some
unevenness and cracking in the layer.
The coating covered the uneven drug layer adequately for all the
samples (Fig. 5), but thinner coatings displayed the same uneven
surface, and higher-resolution images demonstrated coating pro-
blems, such as layers, craters and a rough surface.
The results of the morphological tests indicated that the thickest
coating layer yielded the best quality of surface.4.4. Dissolution of diltiazem hydrochloride from pellets
It is clear from Fig. 6 that every sample underwent 100% drug
release by 60 min in the pH 6.8 dissolution medium. Sample 2, with
the thinnest coating ﬁlm layer, however, yielded more than 10% drug
release in the acidic medium, despite the enteric coating used.
Samples 3, 4 and 5 furnished progressively better results, with no
release exceeding 2.50%. Previous studies showed that the minimum
ﬁlm thickness for achieving gastro-resistance (less than 5% over 2 h in
gastric acid) in aqueous enteric Eudragit coatings is about 50 μm in
tablets [17] and 15% weight gain in pellets [18]. With Arcyl-EZE a
thinner coating (about 30 μm thick and 13% polymerweight gain) was
sufﬁcient.
The standard deviation due to the coating problems tended to be
inversely proportional to the thickness of the ﬁlm on the pellets.
The standard deviations were unusually high. One explanation for
this is the rupture of the ﬁlm coating, which occurs more often in
thinner coatings. The diagram further indicated that thinner ﬁlm
coatings also had a tendency to dissolve more quickly, with higher
drug release patterns early on. Thicker ﬁlm coatings seem to hinder
dissolution (not prevent it, as the ﬁlm dissolves at pH 6.8), but give aFig. 3. Roundness distribution of particles.
Fig. 4. SEM picture of Sample 1 (10.0 kV, ×100 SE(U)).
Fig. 6. Drug release of the coated pellets in simulated gasrtic and intestinal ﬂuid.
158 K. Nikowitz et al. / Powder Technology 205 (2011) 155–159more even dissolution proﬁle, as revealed in the progressively lower
standard deviation values.
5. Conclusions
Our investigations permit the conclusion that Acryl-EZE is suitable
for the making of delayed-release multilayer pellets without the use
of additional excipients. The ﬁlm thickness is easily determined
through image analysis.
Dissolution studies led to the ﬁnding that the ﬁlm thickness directly
inﬂuenced the rate and extent of dissolution in an acidic medium,
and with an observable tendency to hinder dissolution in an alkaline
medium, but this tendency was not highly pronounced because of the
large standard deviations.
For every sample, the drug release in acidic medium greatly
exceeded our expectations based on the ﬁlm thickness. This may have
been due to drug migration into the ﬁlm layer. This idea is supported
by the very good solubility of diltiazem and by the fact that the drug
release in acid is dependent on the ﬁlm thickness.
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The determination of ﬁlm thickness is of prime importance in the quality assurance of
coated pharmaceutical preparations. The rapid measurement of this parameter is prob-
lematic for multi-particulate pellet systems. The aim of this study was to apply the Raman
spectroscopic method for the determination of the thickness of polymer coating on pellets.
The change of Raman intensity was compared with measured ﬁlm thickness, which was
calculated from the change of the geometric parameters of the pellets, measured with an
image-analyzing system. The results revealed that despite some difﬁculties Raman spec-
troscopy is a suitable method for the fast and accurate determination of ﬁlm thickness on
multi-particulate systems.
 2009 Elsevier Ltd. All rights reserved.Table 1
Film thickness and corresponding peak integrals of products.
Film thickness (mm) Integrals
Peak 1 Peak 2 Peak 3
Sample 1 0 0 0 01. Introduction
The thickness of the ﬁlm coating on solid dosage forms
exerts a large effect on the drug dissolution proﬁle of the
preparation. For this reason, the determination of this
parameter is of prime importance in the quality assurance
of controlled release dosage forms. Traditionally, the ﬁlm
thickness can be determined via the addition of a speciﬁc
amount of coating material, or by measurement of the
geometric parameters. Geometric measurements can easily
be performed on tablets, but measurements on granules or
pellets are more difﬁcult due to their size. Such measure-
ments can be made only with image-analyzing techniques,
which are accurate, but time demanding [1]. In recent
years, the use of fast and powerful nondestructive methods
such as interferometry [2] or spectroscopic methods (NIR,
FTIR, Terahertz) has come into focus [3], which can be used
for on line monitoring of the technological process [4,5],
particularly as regards tablet coatings. In the case of pellet
systems, this measurement is more problematic due to the
size ratio of the particles and the laser spot. The present
study relates to the applicability of Raman spectroscopy for
the measurement of the thickness of ﬁlms on pellets.þ36 62545571.
K. Pintye-Ho´di).
. All rights reserved.2. Experimental
The multi-particulate pellet samples were prepared in
a Strea-1 ﬂuid bed Wurster chamber (Niro Aeromatic Ltd.,
Switzerland). In the ﬁrst step, the API was layered onto the
surface of indifferent (without API) cores. Dilthiazem HCl
(Ph. Eur.) and Kollidon 25 (BASF, Germany), in a relative
mass ratio of 5:3, were dissolved in water to give a total
solid content of 40%. The liquid was layered onto the
surface of preheated Cellet 500 (ShinEtzu, Japan) cores at
50 C. The other coating conditions for all batches were:
nozzle diameter 1 mm, peristaltic pump speed 4 rpm, fan
capacity 4.5, air volume 75 m3/h and outlet temperature
43 C. The dry material consumed was 197 g for 200 g of
core. The pellets were further ﬂuidized for 10 min after
layering.Sample 2 15.5 9158 5369 22,155
Sample 3 23.5 11,471 7669 24,926
Sample 4 28.9 11,805 9174 26,077
Sample 5 44.4 13,876 10,416 30,428
Fig. 1. Raman spectra of materials with different measuring distance.
T. Sova´ny et al. / Polymer Testing 28 (2009) 770–772 771After a 10-min drying time, the coating material was
sprayed under the same conditions as above. The coating
liquid was a 20% aqueous dispersion of Acryl-Eze (Colorcon,
UK), a 1:1 copolymer of methacrylic acid and methyl
methacrylate, generally used for enteric coating of dosage
forms. The consumed drymaterial, from Samples 2 to 5was
59.5 g, 79.5 g, 99.3 g and 125.0 g, respectively.Fig. 2. Raman spectra3. Results and discussion
3.1. Measurement of ﬁlm thickness
Film thickness was determined from the results of
image-analyzing measurements. Samples were taken after
the layering of the active pharmaceutical ingredient andof the samples.
T. Sova´ny et al. / Polymer Testing 28 (2009) 770–772772after coating. The geometrical parameters of 300 particles
were determined with a stereomicroscope (Zeiss,
Switzerland) and a Quantimet 500 MC image-analyzing
system (Leica Cambridge Ltd., UK). The mean ﬁlm thickness
was calculated from the difference between the mean
particle diameters of the particles before and after coating.
The image analysis demonstrated that the roundness of
pellets was good, with calculated values in the range 1.07–
1.21. However, there was a small difference between the
smaller and the larger diameter of the particles. These were
around 780 mm and 860 mm respectively for every batch
after layering. The further measurements revealed that the
ﬁlm thickness of the coating layer, which was 15.5, 23.5,
28.9 and 44.4 mm for the various samples (Table 1), corre-
lated well (R2¼ 0.975) with increasing amount of the
coating material.
3.2. Raman spectrometry
The Raman spectra were detected off-line with an
AvaSpec 2048 CCD-array Raman spectrometer (Avantes BV,
The Netherlands) using a standard 785 nm laser. Two
problems occurred during the spectroscopic measure-
ments. The spectra were taken from bulk samples with
a ﬁber optic detector, where the spot size was about three
times larger than the individual particles of the sample. The
scattering of the laser light on the rough surface weakened
the intensity of the Raman signal, so an increase in the
number of scans was necessary. Each spectrum was calcu-
lated as the average of 25 scans, which required about
2 min measurement time. The other problem was that the
API exhibits many characteristic peaks in the Raman shift
range 250–1700 1/cm, which partially overlap with the
characteristic peaks of the coating material at 398, 516 and
640 1/cm (Fig. 1). However, the results indicated a strong
inﬂuence of the measuring distance of the detector on the
peak intensities. The optimal distancewas 6 mm for the API
and 8 mm for the coating material. This difference is a great
advantage during the measurements, which were per-
formed with an 8 mm detector distance, because the
weakening of the signal of the API (Fig 1) helps the deter-
mination of the ﬁlm thickness. Especially in the case of
coated samples, because under these circumstances thesignals of the API were hidden in the noise, the peaks of the
coating material could be determined alone without sub-
tracting the spectra from each other (Fig 2). The integral
values of the peaks were calculated after baseline correc-
tion. The integral values (Table 1) exhibited a strong
correlation with the ﬁlm thickness: the R2 values of the
calibration curves were 0.943, 0.892 and 0.996 respectively
for the different peaks. This tendency clearly indicates that
the estimation of the ﬁlm thickness based on the Raman
spectra improves with the improvement of the signal/noise
ratio.
4. Conclusions
It may be concluded that Raman spectrometry is a suit-
able method for the estimation of ﬁlm thickness. The
measurement requires only a short time as compared with
other methods. The disturbing effects of the different
materials can be eliminated through selection of the
optimal measuring conditions. This permits monitoring of
the ﬁlm thickness even during the coating process.Acknowledgements
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